[Frontiers in Bioscience 5, d938-961, December 1, 2000]

Current Issue

Send correspondence to:

Dr. Richard G. Pestell,
Albert Einstein College of Medicine,
Chanin 302A,
1300 Morris Park Avenue,
Bronx, New York 10461

Tel: 718-430-8662,
Fax: 718-430-8674,
E-mail: pestell@aecom.yu.edu

* These authors contributed equally to the manuscript.


Prostate Cancer, Cell Cycle, Cyclin D1, Transgenic Model, Review


Copyright copy; Frontiers in Bioscience, 1995


Brian T. Zafonte*, James Hulit*, Derek F. Amanatullah, Chris Albanese, Chenguang Wang, Eliot Rosen, Anne Reutens, Joseph A. Sparano, Michael P. Lisanti, and Richard G. Pestell

Division of Hormone-Dependent Tumor Biology, The Albert Einstein Comprehensive Cancer Center, Department of Development and Molecular Biology and the Department of Oncology, Albert Einstein College of Medicine, Bronx, New York 10461

Table of contents

1. Abstract
2. Introduction
2.1. Inherited Breast Cancer Susceptibility Genes
2.2. Breast Adenocarcinoma Pathology
3. The Cell Cycle and Pathogenesis of Breast Cancer
3.1. The p27Kip1 Tumor Suppressor in Breast Cancer
3.2. Oncogenes
3.2.1. Neu
3.2.2. Myc
3.2.3. Ras
3.2.4. pp60c-Src
3.3. Transforming Growth Factor-bs
3.4. Steroid Hormones
3.4.1. The Estrogen Receptor and Breast Cancer
3.4.2. Estrogen Receptor and the Cyclins
3.4.3. Estrogen Receptor and the CKI
4. Angiogenesis
5. Tumor Progression and Metastasis
5.1. Tumor Progression
5.2. Metastasis
6. Novel Therapies
6.1. Targeting the Cell Cycle for Breast Cancer Therapy
6.2. Targeted Therapies Available in the Clinic
6.3. Other Targets for Cancer Therapy
7. Future Directions
8. Acknowledgments
9. References


Breast cancer is the most commonly diagnosed cancer in American women. The underlying mechanisms that cause aberrant cell proliferation and tumor growth involve conserved pathways, which include components of the cell cycle machinery. Proto-oncogenes, growth factors, and steroids have been implicated in the pathogenesis of breast cancer. Surgery, local irradiation, and chemotherapy have been the mainstay of treatment for early and advanced stage disease. Potential targets for selective breast cancer therapy are herein reviewed. Improved understanding of the biology of breast cancer has led to more specific "targeted therapies" directed at biological processes that are selectively deregulated in the cancerous cells. Examples include tamoxifen for estrogen receptor positive tumors and imunoneutralizing antibodies such as trastuzumab for Her2/neu overexpressing tumors. Other novel anticancer agents such as paclitaxel, a microtubule binding molecule, and flavopiridol, a cyclin dependent kinase inhibitor, exert their anticancer effects by inhibiting cell cycle progression.


Breast cancer accounts for about 30% of all cancers diagnosed in women in the United States (an estimated 183,000 new cases in 2000) (1). It is the second leading cause of cancer death in women, accounting for about 15% of all female cancer deaths (an estimated 42,000 deaths in 2000) (1). Breast cancer mortality has declined by an average of 1.8% per year between 1990 and 1996, particularly in white and younger women. This decline is probably due to the more widespread use of screening mammography and perhaps due to improved treatment of early stage disease (2). Risk factors for breast cancer include family history, reproductive status, and lifestyle elements including diet and exercise. Although family history is an important risk factor, approximately 80% of all women with breast cancer have no family history of the disease (3). The molecular analysis of human breast cancer has been propelled by the use of transgenic mouse models. These murine systems have been used both for molecular analysis of candidate oncogenes and tumor suppressors and more recently for the testing of novel therapeutics. In the future, the genetically engineered mouse models may provide important insights into rational therapeutics based on tumor genotyping.

2.1. Inherited Breast Cancer Susceptibility Genes

Although breast cancer is a heterogeneous disease in its clinical and biological manifestations, patients with strong family histories demonstrate a more predictable disease course (4). One large population-based study (CASH study) estimated that 7% of all breast cancers were due to familial breast cancer associated with genetic susceptibility alleles (5). Genes associated with high breast cancer risk (called high-penetrance genes) are: BRCA1, BRCA2, TP53, PTEN, MSH2/MLH1, and STK11 (reviewed in (6)). The last four genes are relatively rare and variants in these genes are associated with the Li-Fraumeni, Cowden, Muir-Torre, and Peutz-Jeghers syndromes respectively. Information on BRCA1 and BRCA2 is available on the Breast Cancer Linkage Consortium Internet site (http://ruly70.medfac.leidenuniv.nl/~devilee/BCLC/statbite.htm) and the Breast Cancer Information Core site (http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic/index.html) (Table 1).

Table 1. Web sites relevant to transgenic studies (from: http://www.aecom.yu.edu/pestell)

Non-murine Transgenics

  • MIT Center for Genome Research


  • Japan Animal Genome Database


  • The Genome Database (H. sapiens)


  • Flybase (D. melanogaster)


  • The Fish Net (D. rerio)


  • Yeast Genome Database (S. cerevisiae)


Murine Transgenics

  • The Jackson Laboratory


  • The Mouse Genome Database


  • Induced Mutant Resources


  • The Transgenic/Targeted Mutation Database


  • The Mouse Atlas Project


  • Portable Dictionary of the Mouse Genome


  • Whole Mouse Catalog



  • Database of Gene Knockouts


  • BioMedNet Mouse Knockout Database


  • UCD Medpath Transgenic Mouse Searcher


  • Nagy Cre and Flox Transgenic Databases


  • Gene trap Insertions


  • Transgenic Systems for Mutation Analysis


Crossing Organisms

  • National Center for Biotechnology Information


  • Genbank


  • Cross-referencing with Mammalian Phenotypes


  • Online Mendelian Inheritance in Man


  • Human/Mouse Homology Relationships


  • Biology of the Mammary Gland


  • The Mammary Transgene Database


  • Human-Mouse Homology Database


Mapping and Sequencing

  • UK Human Genome Mapping Resource Center


  • German Human Genome Project


  • National Center for Genome Resources


  • Genetic Linkage Analysis


  • Stanford Human Genome Center


  • Genethon Human Genome Research Center



  • Pasteur Institute


Inherited mutations of BRCA1 account for 1-5% of human breast cancer and carriers (1/800 in the US) show a lifetime risk of developing some form of cancer of 60-80% (7). More than 140 distinct BRCA1 mutations have been identified in breast and ovarian cancer-prone families. In addition, the reduction in BRCA1 abundance in sporadic breast tumors (8-10) suggests BRCA1 function may regulate tumorigenesis through additional pathways. In families with increased breast cancer susceptibility, BRCA1 mutations occur in 52% and BRCA2 mutations in 32% of breast cancers (11). In families with a history of both breast and ovarian cancers, BRCA1 mutations occur in 81% and BRCA2 mutations in 14% (11), but only 58% of families with site-specific female breast cancer have mutations in BRCA1 or BRCA2. BRCA-associated breast tumors have a 2-3 fold higher incidence (84%) of somatic aberrations in p53 (i.e. mutations in the gene Trp53 or protein accumulation) compared to sporadic grade-matched breast tumors (reviewed in (12)). p53 is a protein involved in cell cycle arrest and apoptosis. The TP53 mutants in BRCA1 and BRCA2-associated tumors include some novel types that fail to suppress transformation, exhibit gain-of-function transforming activity using in vitro studies, yet still retain other wild-type p53 functions (13).

A role for BRCA1 and BRCA2 in DNA repair has also been described ((14-16) (reviewed in: (17)). Phosphorylated BRCA1 or 2 associates with RAD51 (18), a protein required for repair of double strand DNA breaks by homologous recombination (19). BRCA1 participates in an S phase, DNA damage-dependent cell cycle checkpoint response co-localizing with RAD51 and BARD1 (20). Mutations in BRCA1 and BRCA2 may therefore lead to accumulation of damaged DNA, which fails to trigger cell cycle arrest because of defective p53 function. The proclivity towards the predominant involvement of BRCA1 mutations in breast cancer, although relatively ubiquitously expressed, raises the possibility that BRCA1 may interact with components of other pathways that are predominantly dysregulated in human breast cancer. Examples of such interactions are BRCA1 with the estrogen receptor (21, 22) and BRCA1 with mammary oncoproteins including RAS, cMYC, and HER2. In addition, the subnuclear location of BRCA1 is likely important in normal tumor suppressor function, as mislocalization occurs in the presence of these transforming oncogenes (23).

Transgenic approaches to study the function of BRCA1 have been hampered by the embryonic lethality of the Brca1-/- animals at E6.5-9 (14) with partial rescue in the p53 or p21 nullizygous genetic background (24). Mice with mutations in BRCA1 develop tumors with allelic loss of Trp53 (25), consistent with the high rate of TP53 mutations in BRCA1-derived human cancers (26, 27). The Brca1-/- cells grow poorly due to chromosomal loss and are particularly sensitive to ionizing radiation (28) and overexpression of BRCA1 is associated with the induction of senescence or apoptosis (29, 30). Therefore investigators have engineered conditional knockouts for analysis in tissue specific paradigms (31) and remarkably the human BRCA1 gene has been shown to rescue murine Brca1 deficiency, providing an ideal model for studying human BRCA1 function (32).

The associations between candidate polygenes (also called low-penetrance genes) and breast cancer have been less clearly established. These genes include COMT, ATM, CYP1A1, CYP2D6, CYP2E1, GSTM1, HRAS1, and NAT2 (reviewed in (6)).

2.2. Breast Adenocarcinoma Pathology: Implications for Local and Systemic Therapy

Adenocarcinoma is by far the most common malignant neoplasm of the breast. The tumor may have features suggesting a ductal epithelial origin (90%), a lobular origin (5%), or both (5%). These tumors arise from the terminal duct lobular unit, the functional unit of the mammary parenchyma. Invasive ductal and lobular carcinomas metastasize by lymphatic and hematogenous spread to regional lymph nodes and distant sites, carrying the risk of local and systemic recurrence (33). Treatment typically consists of removal of the primary tumor (by lumpectomy or mastectomy) and regional axillary lymph nodes, followed by systemic "adjuvant" chemotherapy or hormonal therapy in order to reduce the likelihood of systemic recurrence. The choice of the local procedure is predicated upon establishing tumor free surgical margins, which may require mastectomy if there is a large tumor, a small breast, or other technical factors that render breast conservation untenable. Lumpectomy is equally curative, although local irradiation is usually indicated following surgery to reduce the risk of local recurrence within the breast (from about 40% to 5-10%). Identification of the "sentinel node" by injection of a dye or radiopharmaceutical into the tumor bed minimizes the extent of axillary surgery and its attendant morbidity if the "sentinel node" has no metastases. The accuracy of the procedure is highly dependent upon the surgeon's experience (34). Ductal carcinoma in situ (DCIS) (3) on the other hand, has the capacity to proliferate but lacks the capacity to invade the basement membrane of the duct and metastasize. The natural history of DCIS is characterized, therefore, by local but not systemic recurrence. Interestingly, lobular carcinoma in situ (LCIS) is associated with an increased lifetime risk of developing both invasive lobular and ductal carcinoma. Its diagnosis does not require any treatment of the primary lesion, and is viewed as a risk factor for the subsequent development of breast cancer.


Breast cancer induction and progression are associated with oncogenic activation, loss of checkpoint control tumor suppressor function, and growth sustained by growth factors and steroids (35, 36). Many candidate mammary tumor suppressors and oncogenes, which have been implicated in human breast cancer through pathological observations, have been assessed using transgenic mouse models. These studies in which candidate oncogenes have been targeted to the mammary gland by mammary gland specific promoters have identified the importance of several types of proteins including growth factors, their receptors, intracellular cell cycle proteins, and cellular proto-oncogenes (Table 2). The recent use of unified pathological classifications for tumors and the shared use of web sites outlining transgenic and knockout animals for use by investigators has catalyzed global productive interactions in breast cancer research (Table 1).

Table 2. Transgenic mouse models of mammary cancer







  • Wnt1




  • Wnt10b




  • Notch4(Int3)




248; 249

  • P-Cadherin



Cell Cycle

  • Myc




102; 251

  • p53-172H



WAP, Null

252; 253

  • Cyclin D1




  • SV40TAg




254 - 256


  • pp60c-src




  • PyV-mT




  • Ras




  • b-catenin Y33








  • Erb-B2/neu




93; 94; 253

  • Ret-1




  • Tpr-MET




  • Cdc37



  • Aromatase



Growth Factors

  • FGF3(Int2)




260; 261

  • FGF7(KGF)




  • Heregulin





  • HGF






BGL, H19

265; 266

  • TGF-a

p53-172H; Myc; DMBA



269; 270

  • TGF-b





The promoter and the transgene used to drive mammary gland restricted expression are detailed (from (245)).

3.1. The Cell Cycle in Breast Cancer

During breast cancer development, cell cycle deregulation promotes cellular hyperplasia and tumor cell growth. Abnormal gene expression is common, including increased oncogene activity (c-ErbB-2, c-Ras, c-Myc) and loss of tumor suppressor function (p53, pRB). In addition, the aberrant expression of cell cycle mediators contributes to the transformation of normal mammary cells.

The mammalian cell cycle (Figure 1) consists of four stages: S phase, where DNA synthesis occurs, mitosis (M) during which the actual cell division takes place, and two gap or growth phases (G1,G2) during which required cell components are replicated. A quiescent non-proliferating state is termed G0. Mitogen-induced signaling orchestrates the expression of kinase holoenzymes that coordinate the stepwise (G1, S, G2, M) progression through the cell cycle. Each kinase holoenzyme consists of a regulatory subunit, the cyclin, and its catalytic partner, the cyclin-dependent kinase (CDK). The mammalian cyclin family (cyclins A-H), selectively bind members of the Cdk family. Phosphorylation of these specific cyclin-Cdk heterodimeric complexes by a Cdk activating kinase (CAK) activates holoenzyme activity. The cyclin dependent kinase inhibitors (CKIs) attenuate holoenzyme function (Figure 1) The cyclin-Cdk complexes promote cell cycle progression through specific stages or "checkpoints" by stimulating gene expression of transcription factors and critical cell cycle components.

Figure 1. The mammalian cell cycle (from: (40)). Orderly progression through the cell cycle involves passage through sequential checkpoints. Full holoenzyme activity of the cyclin D1-Cdk4 complex is induced by mitogen recruitment of CAK. The cyclin D1-Cdk4 complex phosphorylates the pRB protein leading to sequential phosphorylation by cyclin E-Cdk2 and release of free E2F. The phosphorylation of pRB, and relief of transcriptional repression by pRB induces genes involved in the induction of S-phase entry.

Together with its catalytic subunits, Cdk4 and Cdk6 (37), the cyclin D1 holoenzyme complex phosphorylates the retinoblastoma tumor suppressor protein pRB (38-40). Expression of cyclin D1 is induced early thereby promoting G1 phase cell cycle progression in mammalian cells. The structurally related D type cyclins, D2 and D3, are also capable of heterodimerizing with Cdk4/6 and phosphorylating pRB in vitro (40). Phosphorylation of pRB is essential for passage through the restriction point in G1, and represents the critical step after which the cell is then committed to another round of division. Cyclin D1 binds to and sequesters cell cycle inhibitors such as p27Kip1 (Figure 2), which thereby contributes indirectly to the promotion of cell cycle progression.

Figure 2. Dual function of p27Kip1. The cyclin D1 gene product binds its catalytic subunit partner (Cdk4) in the presence of an assembly factor. The cyclin D1-Cdk4 holoenzyme is phosphorylated by a Cdk activating kinase (239) (CAK), which consists of several subunits. Activated cyclin D1-Cdk4 can then phosphorylate its target substrate, the tumor suppressor pRB. Cyclin E-Cdk2 also phosphorylates pRB. The role of the p21 CKI family, shown as p27Kip1, in regulating activity of the cyclin D1-Cdk complex is controversial. In some circumstances p27Kip1 is thought to inhibit activity of the complex (240). In other circumstances, p27Kip1 does not inhibit activity of the complex (241) acting as an assembly factor (48). If p27Kip1 inhibits cyclin E-Cdk2 but does not inhibit cyclin D1-Cdk4, cyclin D1 induction may promote S-phase entry by titrating p27Kip1 from an inhibitory complex with cyclin E-Cdk2. These findings suggest the stoichiometry or cell-type may be important in the action of p27Kip1.

The cyclin E-Cdk2 complex promotes cell cycle progression by pRB hyper-phosphorylation, likely functioning temporally downstream of cyclin D1 (41).

cyclin E-Cdk2 activation is also necessary for initiation of centrosome duplication and phosphorylates several substrates in regulating these activities including p220NPAT (42) and nucleophospmin/B23 (43) (Figure 3). Cyclin A also triggers S phase entry coupled to Cdk2 and in cooperation with cyclin E (44). Cyclin E colocalizes with p220NPAT in Cajal bodies, subnuclear bodies involved in histone gene expression, coincident with p220NPAT phosphorylation at the G1/S boundary, suggesting an important link between cyclin E-Cdk2 and histone gene expression (45). Cyclin H phosphorylates the cyclin D1/Cdk/pRB complex and is necessary for full cyclin D1 activity (37, 46). The differential expression of cyclins and Cdks is highly coordinated and regulated in large part by growth factors.

Figure 3. Cell cycle-regulated, cyclin E-Cdk2-dependent S-Phase phosphorylation events. (Top) Cyclin E-dependent phosphorylation of p220NPAT is required for the S-phase induction of the histone H2B promoter. p220NPAT is co-localized with Cajal bodies at histone gene clusters. Activation of cyclin E-Cdk2 complexes results in a cyclin E-Cdk2-dependent, ubiquitin/proteasome-mediated reduction of cyclin-Cdk inhibitor p27KIP1 abundance. Reduction is initiated by the threonine-specific phosphorylation of p27KIP1 by catalytically active cyclin E-Cdk2, followed by a JAB1-dependent p27KIP1 cytoplasmic translocation. (Bottom) Centrosome duplication is blocked by nucleophosmin (NPM/B23). Cyclin E-Cdk2-dependent phosphorylation of NPM/B23 drives its dissociation from centrosome pairs. Centrosome separation and duplication now proceeds, as both are required for mitosis.

Two families of cyclin-dependent kinase inhibitors (CKIs), Cip/Kip and INK4, inactivate cyclin-Cdk holoenzyme complexes (39, 40, 47). Members of the Cip/Kip family include p21Cip1, p27Kip1, and p57Kip2, whereas p16INK4a, p15INK4b, p18INK4c, and p19INK4d comprise the INK4 inhibitor group. The INK4 CKIs inhibit the catalytic domains of Cdk4 and Cdk6. The broader acting Cip/Kip family inhibits the activity of cyclin D-, E-, and A-dependent kinases. In a manner that is not well understood, p21Cip1 and p27Kip1 may also serve an assembly role in cell cycle regulation (48, 49). The Cip/Kip family can promote cyclin D-Cdk4 assembly and promote holoenzyme nuclear localization (49, 50). Several studies have documented that overexpression of the CKI can inhibit mammary epithelial

cell proliferation. For this reason consideration has been given to using the CKIs in tumor suppressor gene therapy for breast cancer.

The cell cycle becomes deregulated during oncogenic transformation in association with failure of normal restriction point control. Overexpression of cyclins (D and E), pRB inactivation, and reduced CKI activity are frequent findings. The incidence of abnormalities of the cyclin D1/Cdk4/p16/pRB axis in human cancers is second only to that of p53 abnormalities (37). Cyclin D1 is overexpressed in 30-45% of human breast carcinomas (40), and in cooperation with other misexpressed genes, contributes to the oncogenic transformation of normal mammary cells. The role for cyclin D1 as a "driver oncogene" has been demonstrated in transgenic mice overexpressing cyclin D1 (51). Many oncogenes, including activating mutants of Ras, pp60src, Rac, Dbl, and Neu, induce cyclin D1 abundance through inducing cyclin D1 promoter activity (52-56). The mechanism of cellular transformation is believed to occur mainly through the phosphorylation and inactivation of pRB (39) and cyclin D1-mediated sequestration of CKIs. In contrast to cyclin D1 overexpression in human breast cancer, cyclins D2 and D3 are not associated with breast tumor formation.

3.1.1. The p27Kip1 Tumor Suppressor in Breast Cancer.

The p27Kip1 protein was initially characterized as a protein homologous to the tumor suppressor p21Cip1.

When overexpressed in fibroblasts, cell cycle progression was delayed and anti-sense p27Kip1 experiments demonstrated mitogen-independent G1-phase progression, indicating a critical role for p27Kip1 in the establishment or maintenance of cellular quiescence (57, 58). Reduced p27Kip1 levels are found in a variety of tumors including breast cancers. Reduced p27Kip1 levels have independent prognostic significance in a subset of tumors. Although loss of a single p27Kip1 allele is not uncommon in human tumors, the second allele is frequently wildtype (59). Thus p27Kip1 does not fit the classic tumor suppressor paradigm (59).

The abundance of p27Kip1 is regulated primarily at a post-translational level, although translational control also contributes to p27Kip1 protein regulation (Figure 4). Thus p27Kip1 mRNA levels remain relatively unchanged during the cell cycle transition however, the addition of mitogens reduces p27Kip1 protein levels. For example in quiescent 3T3 cells p27Kip1 protein levels decrease after mitogenic stimulation (60-62). In human breast tumors p27Kip1 degrading activity is increased. The degradation of p27Kip1 upon mitogen stimulation is regulated by antecedent phosphorylation. Cyclin E-Cdk2 induces p27Kip1 phosphorylation on T187 (63). A threonine-187 to alanine mutant of p27Kip1, created a p27 protein that caused a G1 block resistant to cyclin E overexpression and whose level of expression was not modulated by cyclin E. Phosphorylation of p27Kip1 by cyclin E-Cdk2 enhanced degradation of p27Kip1 thereby promoting G1-S phase transition. Thus, the cyclin-Cdk complexes promote cell cycle progression in mammalian cells by enhancing degradation of the CKI. The growth factor mediated reduction in p27Kip1 protein levels is mediated primarily through enhanced ubiquitin-mediated degradation (64). The substrate specificity of the ubiquitin ligases, called SCFs (composed of Skp1, Cul1, and F-box proteins), is determined by the specific F-box protein, which binds the substrate. The F-box protein that regulates b -catenin abundance is termed b -Trcp (65) and the p27Kip1 F-box protein is called Skp2 (66). The abundance of Skp2 may therefore be rate limiting in the destruction of p27Kip1. Skp1 by contrast is involved in binding cyclin D1 and p21Cip1 (67). Several lines of evidence suggest that Skp2 may function as an oncogene. Skp2 is frequently found overexpressed in tumor cell lines, collaborates with Ras in transformation, and can promote S-phase entry of quiescent cells. The role of specific oncogenes in regulating Skp2 abundance remains to be determined.

Figure 4. p27Kip1 degradation. Nuclear p27Kip1 is phosphorylated by cyclin E-Cdk2 in a trimeric complex. The Jun co-activator JAB1 also binds to phosphorylated p27Kip1 enhancing its nuclear-cytoplasmic translocation and sequential ubiquitination by the SCF complex, and proteasomal mediated degradation.

The p21Cip1/p27Kip1 family of proteins are "dual function" kinase inhibitors, either inhibiting or inducing Cdk activity. The p21Cip1 family members have a conserved region near the amino terminus which is necessary and sufficient for binding to and inhibiting Cdk2 (68-70). Functional sub-domains of p21Cip1 were defined through deletional analysis. The binding of p21Cip1 to cyclin E-Cdk2 and cyclin A-Cdk2 was shown to involve both a Cdk2 binding domain and either an amino terminal or carboxy terminal cyclin binding domain, whereas binding by cyclin D1 involved only the amino terminal cyclin binding domain (71). The carboxy terminal region of p21Cip1 allows it to associate with proliferating cell nuclear antigen (PCNA), a processivity subunit of the DNA polymerase d holoenzyme (68-70, 72, 73). Because the binding of p21Cip1 to PCNA inhibits the processivity of polymerization but does not affect excision repair, it was suggested that p21Cip1 may serve to coordinate DNA replication with cell cycle progression (74). p21Cip1 inhibits Cdk activity in a kinase and concentration-dependent manner (75) inhibiting Cdk4 and Cdk6 kinase activity with a Ki of 0.5-15 nM, but is a poor inhibitor of cdc2/cyclin B in vitro with a Ki of 400 nM (76).

The cyclin-Cdk complex to which p27Kip1 is bound determines its functional activity. p27Kip1 is found associated with cyclin E in a variety of cell types during quiescence (60, 77). When bound to cyclin D1-Cdk4, p27Kip1 may not be inhibitory (77-80) whereas cyclin E-Cdk2 activity is inhibited by p27Kip1. It is thought that the removal of p27Kip1 from the cyclin E-Cdk complex is an essential step for S-phase entry. Through binding cyclin D1-Cdk4, p27Kip1 is sequestered from cyclin E-Cdk2, reducing its inhibition by p27Kip1 (77-80).

3.2. Oncogenes

3.2.1. Neu

The neu (c-ErbB-2, HER-2) proto-oncogene encodes a glycoprotein receptor tyrosine kinase (RTK). Neu is a member of the growth factor receptor family that includes the epidermal growth factor (EGF) receptor (ErbB-1), ErbB-3, and ErbB-4. Amplification and overexpression of neu is observed in 20-30% of invasive human breast tumors (81-83), and overexpression of Neu correlates with breast cancer progression and a poor prognosis (84-87). The neu receptor family stimulates mitogenesis through ligand-induced formation of hetero- and homodimeric signaling complexes (88). Increased neu expression induces a signaling pathway involving Ras and Src (89-91). An activating mutation in the transmembrane region of rat Neu (known as NeuT) (92) induces mammary carcinoma with high frequency when overexpressed in transgenic mice (93, 94). Similarly, wildtype Neu overexpression in transgenic mice demonstrated tumor formation associated with development of somatic mutations of the neu transgene (95). The transforming ability of Neu has been linked to cell survival and through mitogenic signaling pathways to the cell cycle regulatory machinery (Figure 5). Cyclin D1 has been identified as a downstream target of oncogenic neu in MMTV-Neu transgenic animals, and increased cyclin D1 activity is required for neu-induced transformation (53). The p27Kip1 tumor suppressor inhibits Neu-induced transformation in mammary epithelial cells in vivo, consistent with the clinical findings that reduced p27Kip1 levels in human breast cancer confer adverse prognostic significance.

Figure 5. ErbB-2 receptor pathway, cell survival and proliferation. Upon activation, the ErbB-2 receptor induces several downstream signaling pathways including the ERK and PI3K pathways. Induction of the ERK pathway is associated with the induction of cyclin D1 transcription (53) and the induction of JAB1 nuclear translocation (242). Cyclin D1 is required for proliferation and contact-independent growth. The Akt pathway is also an important downstream target of ErbB-2 and is likely involved in cell survival (243). Specific sites within the ErbB-2 cytoplasmic loop contribute to the induction of the metastatic phenotype (244).

3.2.2. Myc

The c-myc oncogene has also been implicated in the pathogenesis of human breast cancer. myc amplification and subsequent overexpression is one of the most common genetic abnormalities seen in breast cancer. Although present in about 15-40% of human breast cancer cases (96-99), Myc overexpression has not been definitively identified as a poor prognostic marker. The myc gene encodes a nuclear phosphoprotein transcription factor that controls cellular proliferation, differentiation, and apoptosis through distinct domains (100). Anti-sense experiments have demonstrated Myc is necessary for estrogen-induced proliferation in breast cancer (101) and mammary targeted expression of c-Myc induces mammary adenocarcinoma (102-104). Activated mitogenic signals (from the MAP kinase pathway) induce Myc activity and the Myc protein heterodimerizes with MAX to regulate gene expression (35, 105). The mechanisms by which Myc transforms cells is complex and may involve a number of processes such as cell cycle activation and apoptosis. Myc has been shown to inhibit pRB function, repress cellular apoptosis, and regulate phosphatases such as cdc25A (106). Myc can also trans-repress several genes including tumor suppressors (107). p27Kip1 function has been shown to be antagonized by Myc, while (108) components of the cell cycle such as cyclin E-Cdk2 (109, 110), cyclin D1, cyclin D2 (111), and cyclin A are shown to be induced by Myc activity (112) (reviewed in (113).

3.2.3. Ras

The ras gene plays an essential role in cell proliferation (114), development, (115) and differentiation (116-119). Aberrant expression of Ras in human breast cancer has not been well demonstrated except for a correlation between a mutated H-ras-1 locus and aggressive breast cancer (120). Mammary targeted overexpression of activated Ras is sufficient for the induction of mammary tumorigenesis which was associated with the induction of cyclin D1 and a reduction in the abundance of a putative tumor suppressor caveolin-1 (121, 122). Receptor-mediated Ras signaling promotes cyclin D1 activation through the initiation of a kinase cascade, where the sequential actions of Raf/Mek/ERK kinases up regulate the cyclin D1 promoter (54, 61, 123). Although it has not been formally established that the induction of cyclin D1 is required for Ras-induced mammary tumorigenesis, Ras-induced skin tumors were markedly reduced in the cyclin D1-/- background, thereby strongly supporting previous studies implicating cyclin D1 in Ras-induced transformation in fibroblasts (124).

3.2.4. pp60c-Src

The pp60c-src proto-oncogene encodes a 60 kDa cytoplasmic non-receptor tyrosine kinase (125) which is sufficient to both initiate and maintain cellular transformation (126). Activation of the pp60c-src tyrosine kinase has been observed in a large proportion of human breast malignancies (127). Overexpression of a constitutively active mutant of pp60c-src under control of the murine mammary tumor virus long terminal repeat (MMTV-LTR) in transgenic mice induced mammary gland tumor formation (128). The cell cycle regulatory targets of pp60src in mammary epithelial cells and the intracellular kinase pathways by which pp60src regulates cell cycle regulatory pathways are being actively explored. In fibroblast cell lines, pp60v-src enhanced the rate of G1 phase progression in association with an induction of cyclin D1 protein levels in NIH3T3 cells, implicating cyclin D1 in pp60v-src action (129). In mammary epithelial cell cultures, pp60v-src induced cyclin D1 protein levels and promoter activity (52). Furthermore, cyclin D1-associated kinase activity and protein levels were increased in mammary gland tumors from pp60c-src527F transgenic mice. Chemical inhibitors and dominant negative mutants demonstrated optimal induction of cyclin D1 by pp60v-src and involved the MAPK1,2/ERK1,2, the p38, and Jun N-terminal kinase (JNK) members of the mitogen activated protein kinase (MAPK) family. pp60v-src activation of cyclin D1 involved a cAMP response element/activating transcription factor (CRE/ATF) site (52).

pp60c-src likely plays at least a permissive role in promoting cell survival and angiogenesis. Overexpression of Neu leads to pp60c-src activation (130) and leads to anchorage-independent growth in human breast epithelial cells (131). pp60c-src is also necessary for HGF-induced growth and motility of mammary carcinoma cells (132). Inhibition of pp60c-src kinase activity in cells overexpressing pp60c-src and Neu inhibits the anti-apoptotic protein Bcl-XL and leads to reversal of the transformed phenotype (133). pp60c-src induces vascular endothelial growth factor implicating pp60c-src in mammary tumor angiogenesis (134). Together, these studies suggest the src tyrosine kinase regulates tumor cell proliferation, apoptosis, and influences angiogenesis, while enhancing the tumorigenic properties of other RTK oncogenes.

3.3. The Transforming Growth Factor-b family

The transforming growth factor-b s (TGFb ) are members of a superfamily that regulate cell growth and function (135). The TGF-b s are widely expressed inhibitors of cellular proliferation and are strongly implicated as components of a tumor suppressor pathway in different organ systems (136-139). The TGFs are secreted by human breast cancers and in various transgenic mice models (140-143). TGF-b , found in malignant mammary tumors (144-146) normally acts as a growth suppressor, but when overexpressed, enhances tumor formation (146, 147). The mechanisms by which TGF-b 1 inhibits the cell cycle apparatus are highly cell-type and context-dependent. TGF-b 1 activates several downstream signaling pathways including the Smad transcription factors (148-150). In cultured cells TGF-b 1 can inhibit growth by inducing the expression of the Cdk inhibitors (p15INK4B/MTS2 and p21Cip1), through altering the distribution of p27Kip1 from Cdk4/6 to Cdk2 (79) and through inducing inhibitory Cdk tyrosine phosphorylation (151). The cdc25 phosphatases activate the Cdks by dephosphorylating their inhibitory tyrosine and threonine phosphorylated residues (152, 153). In tissue culture experiments (151), and in transgenic mice (154), TGF-b 1 increases Cdk tyrosine phosphorylation through repression of the Cdk-activating tyrosine phosphatase cdc25A. Recent studies suggest that TGF-b 1 may alter the binding of histone deacetylase proteins (HDAC1) to pocket proteins including pRB, p130, and p107, and that HDAC1 may be thereby recruited to specific promoters to induce transcriptional repression (154). Whether HDAC pocket protein associations are altered in breast cancer remains to be determined. However, this area is of interest in view of the highly specific HDAC inhibitor drugs becoming available for cancer treatment (155-158).

3.4. Steroid Hormones

Steroid hormones induce breast cellular proliferation. Estrogen stimulates cell cycle progression early in G1 (159-161), and the induction of cell proliferation was shown to correlate with increased expression of cyclin D1 (162-164). Estrogen accelerates G1/S phase entry through upregulation of cyclin D1-Cdk4 and cyclin E-Cdk2 kinase activity together with modulation of CKI function. Progestins also affect cell cycle activity. In breast cancer cell lines, progestins both stimulated and inhibited cell cycle progression. Progestins transiently induced G1 phase activity by up regulating cyclin D1, then upon completion of the cell cycle, caused cell cycle arrest in G1 (165-168). The significant role of steroid hormones in the pathogenesis of breast cancer is evidenced by the importance of using reproductive factors and exogenous hormone levels as risk factor determinants. Furthermore, the protective effect of early menopause and the demonstration that the selective estrogen receptor modulator, tamoxifen, reduces (by about one-half) the risk of breast cancer in women who are at high risk for the disease, adds further weight to this significant role for steroid hormones.

3.4.1. The Estrogen Receptor and Breast Cancer.

Steroid hormones mediate diverse effects on cellular proliferation, in association with modulating the activity of the cyclins and the CKIs. The proliferative effects of estrogen on responsive tissues, including breast and uterus, have been well documented (for reviews see (35, 36, 165)). The use of animals homozygously deleted of the estrogen receptor alpha gene (ERa knockout mice) confirmed the requirement for ERa in normal mammary gland ductal growth (169, 170), angiogenesis (171), and spermatogenesis (172).

A primary mechanism of estrogen action is the ligand-dependent steroid hormone receptor activation through specific response elements of target genes (173, 174). In addition, estradiol regulates the Ras/Raf/MAPK pathway with similar kinetics to polypeptide growth factors operating through membrane tyrosine kinase receptors (175). Peptide growth factors also modulate ERa activity independently of ligand (176) and the ERa is capable of interacting with a number of other transcription factors to coordinate expression of downstream target genes, including Sp1 and members of the AP-1 family (177). In part, the coordinated regulation of these downstream transcription factors is regulated by interaction with high molecular weight co-integrator proteins, including SRC-1, RIP-140, SNF2b -BRG1 (178), TASF(II)130 (179), and TIFI (180) (reviewed in (181)).

3.4.2. Estrogen Receptor and the Cyclins.

The prognostic significance of cyclin D1 and ERa in human breast cancer has been an area of some ongoing controversy (182). A substantial recent study demonstrated that overexpression of cyclin D1 mRNA correlates with a worse prognosis within the ER-positive breast cancer phenotype and may be a contributing factor to the development of endocrine resistance in ER-positive disease (183). These and other studies have contributed to an interest in defining the molecular mechanisms by which estrogens induce components of the cell cycle regulatory apparatus to induce cellular proliferation. Estrogens stimulate cell cycle progression early in G1 phase in cultured breast epithelial cells (159-161). Cyclin D1 expression is reduced by anti-estrogen treatment in T47-D cells (184). The induction of cellular proliferation by estrogen in breast cancer cell lines was found to correlate with increased expression of cyclin D1 protein levels and cyclin D1 kinase activity in MCF-7 and T-47D cells (162-164). In the experiments conducted by Altucci, cell cycle arrested MCF-7 cells were released from this arrest by 24-48 hrs of treatment with the hydroxymethylglutyryl (HMG) Co-A reductase inhibitor, simvastatin, followed by estrogen treatment. Under these experimental conditions, cyclin D1 protein levels were induced rapidly between 1-3 hours. The induction of cyclin D1 protein levels could be blocked at the mRNA level by actinomycin D, suggesting a role for RNA polymerase II. The cyclin D1 promoter was also induced by estrogens indicating that induction by estrogen may be a direct transcriptional event (163).

Cyclin D1 binds directly to the estrogen receptor and regulates estrogen-dependent enhancer activity (185, 186). The transactivation function of ERa , when fused to a GAL-4 DNA binding domain, was enhanced by overexpression of cyclin D1. This activity was induced further by the addition of estrogens, an effect that was mediated through the EF domain of the ERa (185, 186). Cyclin D1 activated the ERa -mediated transcription in the absence of ligand and the induction occurred independently of the Cdk or pRB binding domains of cyclin D1 (185, 186). Because ERa status is often positive in the post menopausal women, it has been proposed that the overexpression of cyclin D1, which is frequently seen in ERa positive tumors, may function to promote ERa activation of target genes in the presence of low estrogen levels. Through analysis of the molecular mechanisms by which cyclin D1 enhances ERa activity, cyclin D1 was found to bind the ERa co-activator SRC-1 through a carboxyterminal LLXXXL motif, with deletion of this region reducing ERa activation by 80% (187). Because the LXXL motif of SRC-1, which was required for cyclin D1 binding (187) is a conserved motif amongst several co-activators (188), these studies imply cyclin D1 may interact with other co-activator proteins. Thus, cyclin D1 stimulation of estrogen enhancer activity shows that cyclin D1 mediates hormonal effects on target gene sequences by Cdk-independent mechanisms. Cyclin A overexpression also enhances ERa activity and ERa is phosphorylated between amino acids 82 and 121 in vitro by cyclin A, an effect that was inhibited by p27Kip1 overexpression (189). Although most of the studies described above have focused on the ERa gene, ERb mRNA abundance is regulated by the ERa gene (190). In addition, ERa and ERb genes differentially regulate AP-1 activity (191), suggesting that the regulation of the Cdks by estrogens is under complex feedback loops.

3.4.3. Estrogen Receptor and the CKI

The CKIs are also important in estrogen-induced mitogenesis in breast cancer cell lines. Overexpression of p16INK4a for example, blocked the estrogen-induced S-phase entry in MCF7 cells (192), indicating a critical role for the CKIs in estrogen induced mitogenesis. The mechanisms by which estrogen regulates CKI function can be mechanistically considered as three distinct but functionally inter-related effects. Firstly, estrogen treatment induces alterations in the subcellular localization of the CKIs. Estrogens induce cyclin E-Cdk2 activity in association with an alteration in the relative distribution of p21Cip1 from an inhibitory cyclin E-Cdk2 complex to the cyclin D1-Cdk4 complex (193). Because p21Cip1 can inhibit cyclin E-Cdk2 activity, but at specific stoichiometric ratios may foster cyclin D1-Cdk4 activity, the net effect of the relocation of p21Cip1 is to promote cell cycle progression and cellular proliferation (193). Secondly, estrogen alters the nature of the multimeric complexes formed between the cyclin-Cdk complexes. In studies by Prall et al. (1997), estrogens reduced the amount of the Cdk inhibitors p21Cip1 and p27Kip1 protein bound to cyclin E-Cdk2 (194). Thirdly, estrogen treatment results in the formation of higher molecular weight complexes of cyclin E-Cdk2 which lack p21Cip1 and p27Kip1. These high molecular weight complexes contained increased Cdk2 phosphorylation at Thr 160. Therefore, the estrogen-induced activation of cyclin E-Cdk2 appeared to involve both a reduction in the associated CKIs and increased CAK activity. The use of gel filtration chromatography was critical to demonstrating the alterations in the cyclin/Cdk/CKI multimeric complexes. The nature of these high molecular weight complexes is currently unknown, however it is possible that these complexes include estrogen receptor co-activator proteins, such as SRC-1 or p300.

In recent studies of estrogen action both cyclin D1-Cdk4 kinase activity and cyclin E-Cdk2 activity were induced by estrogens. Myc expression is also induced by estrogens and forced overexpression of Myc in MCF7 cells induces similar changes in cyclin E-Cdk2 activity to those induced by estrogen treatment (195). Thus, overexpression of Myc, cyclin D1, or estrogen treatment each result in decreased association of p21Cip1 with cyclin E-Cdk2 and result in the formation of a high molecular weight multiprotein complex with high levels of histone H1 kinase activity (195).


The development of new blood vessels, or angiogenesis, is essential for tumor survival. Normal breast tissue contains numerous angiogenic agents, particularly vascular endothelial cell growth factor (VEGF) and basic FGF, that may promote new blood vessel growth during early oncogenesis (196). This is particularly important in rapidly growing cancers where the native blood vessels can no longer sustain the increased metabolic requirements of the growing tumor. Histological progression from hyperplasia through CIS to invasive carcinoma is associated with development of distinct microvascular patterns and a complex pattern of increased angiogenic factor expression (196, 197). Not surprisingly, the degree of distant tumor growth (metastasis) is directly proportional to the number of capillaries nourishing the tumor (35). Neovascularization in breast cancers is enhanced by growth factors, including FGFs and TGFs, and endothelial-derived factors (198).


5.1. Tumor Progression

Amplification of c-ErbB-2 and Myc in human breast cancer may be an early indication of DNA instability (199). The progression of breast cancer is characterized by the increased activity of transcriptional activators. The activity of the Activator Protein-1 (AP-1) transcription factor complex may be involved in the loss of growth factor-dependence (200). Invasive carcinoma cells differentially express genes for apolipoprotein D, chemotactic cytokines such as RANTES, angiogenic factors such as tissue factor precursor, chromatin remodeling factors SWI/SNF, and matrix proteins (201). The development of laser capture microdissection and high density cDNA microarrays are powerful new techniques that will allow a more detailed analysis of gene expression profiles during tumor progression in human breast neoplasia.

5.2. Metastasis

The spread of cancer, or metastasis, characterized by tumor cell invasion of surrounding tissues with sustained growth at distant sites, is the primary cause of mortality in breast cancer. The induction of angiogenesis and the evasion of host immune responses, together with cell proliferation rates at metastatic sites are also important factors in the metastatic process. An increasing number of gene products have been identified that contribute to invasion and detachment of cancer cells from the primary tumor. Furthermore, blood and lymph vessel mediated transport, extravasation, and tumor cell arrest at distant tissues are also critical for metastasis (202, 203). Genes involved in breast cancer metastasis include mts-1, nm23, WDNM-1, WDNM-2, pGM21, and stromelysin-3 (204-208). The expression of mta1 for example correlated with a high metastatic potential in both rat and human breast cancer metastasis models (209). The identification of these genes may provide rationale basis for targeted anti-metastatic breast cancer therapy.


6.1.Targeting the Cell Cycle for Breast Cancer Therapy

Strategies for reducing breast cancer mortality include screening, prevention, and improving the treatment for early and advanced stage disease. As metastatic disease is generally considered incurable, improving the treatment of early stage disease represents a more prudent strategy to reduce mortality. Surgery, hormonal therapy, chemotherapy, and irradiation have been the mainstays of treatment for curing early stage disease. Despite surgical removal of the primary tumor, relapse at local or distant sites may occur within a few months to more than 40 years after presentation, although most relapses occur within five years after primary therapy (210). The risk of relapse is dependent principally upon the disease burden (as reflected by the number of axillary lymph nodes containing metastases) and upon the virulence of the tumor (as reflected by poor nuclear grade, the expression of certain oncogenes, or other biological factors). Cytotoxic therapy administered after surgery ("adjuvant therapy") results in a relatively modest 25-35% reduction in the risk of relapse (211), presumably by eradicating micrometastatic disease below a critical threshold that is necessary for the development of clinically evident metastases. Cytotoxic therapy kills neoplastic cells by multiple mechanisms including DNA damage (alkylators), disturbing metabolic pathways (antimetabolites), or interfering with DNA repair mechanisms (anthracyclines), elements that are also shared by normal cells. The non-specificity of these agents, therefore, also produces undesirable side effects, including short term (myelosuppression) and long term toxicities (cardiomyopathy, acute leukemia).

Strategies for modulation of the cell cycle (as reviewed by: (212)) include direct or indirect inhibition of the Cdks. Indirect strategies include overexpression of endogenous Cdk inhibitors (e.g., lovastatin-induced upregulation of p21Cip/Waf1, p27Kip1), small peptides that mimic endogenous Cdk inhibitors, depletion of cyclin/Cdk subunits (e.g. antisense molecules), or modulation of proteasomes and upstream phosphatases and kinases. Direct strategies include the use of small molecules that directly inhibit the Cdks, such as purine derivatives and the paullones (212). The small molecule inhibitors that have been most extensively studied in the clinic include flavopiridol and staurosporine (UCN-01) (213). For flavopiridol, diarrhea, nausea, vomiting, neutropenia, and fatigue are representative dose limiting toxicity indicators (214). Minor response or disease stabilization has been observed in some patients with lymphoma, renal cell carcinoma, and colonic carcinoma (214). Experience with staurosporine has been much more limited. Toxicities have included nausea, vomiting, insulin resistance, and pulmonary toxicity (212).

6.2. Targeted Therapies Available in the Clinic

Several "targeted therapies" that selectively effect cancerous cells are currently available in the clinic (212). Estrogens interact to promote cellular proliferation through interactions with the cell cycle apparatus. The selective estrogen receptor modulator tamoxifen reduces the risk of relapse by about 50% when used in the adjuvant setting with considerably fewer side effects than chemotherapy in individuals whose tumor expresses the estrogen receptor. Trastuzumab (Herceptin), a humanized monoclonal antibody that is directed against HER2/neu proto-oncogene produces significant (gt; 50%) tumor regression in about 15% of patients with Neu-overexpressing metastatic disease that is refractory to conventional therapy, and in about 23% of patients when used as first line therapy (215). The addition of trastuzumab to standard chemotherapy significantly improves response rate, response duration, and survival (216). Trastuzumab action involves multiple mechanisms including induction of signal transduction pathways that favor apoptosis, cell cycle perturbation, antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and inhibition of nuclear excision repair mechanisms that confer alkylator agent resistance (217). Studies are now in progress that will evaluate trastuzumab in the adjuvant setting (218).

Taxanes are a third example of relatively selective therapies (paclitaxel and docetaxel), but exhibit considerably less specificity than tamoxifen or trastuzumab. The taxanes bind to tubulin, promote assembly of microtubules, and inhibit their depolymerization (219). In addition to their microtubule effects, the taxanes induce apoptosis (220), inhibit angiogenesis (221), invasiveness (222), cell motility, and metalloproteinase production (223). Paclitaxel is approved for the treatment of early stage breast cancer since it reduces the risk of relapse by about 20% when used as a component of adjuvant cytotoxic therapy (224). Other studies are currently in progress to determine whether other taxanes or taxane-like agents are more effective than paclitaxel, such as docetaxel, epithilone-B, taxopterin, and tularik.

6.3. Other Targets for Cancer Therapy

The matrix metalloproteinases, a family of enzymes that are critical for the metastatic cascade and neoangiogenesis, are a promising target. Numerous inhibitors of the metalloproteinases are currently being tested in the clinic, and some trials have demonstrated that some of these agents may delay progression of some tumor types (225, 226). Some anti-angiogenic agents have shown some efficacy in vascular tumors such as Kaposi's sarcoma (227, 228), although experience with these agents in breast cancer has thus far been limited and less encouraging (229).

Farnesyltransferase has been a target of particular interest in Ras-dependent cancers, since post-translational farnesylation of Ras is necessary for cellular transformation (230). In a transgenic mouse study of farnesyltransferase inhibitors (FTIs), and using mammary specific overexpression of activated Ras, it was demonstrated that FTIs inhibited the formation of malignant mammary tumors in these mice (231). Surprisingly, the FTIs also had activity in tumors lacking Ras mutations and may thus mediate their effects via alternative mechanisms (232). Several of these agents are being studied in the clinic, although they are in the very early stages of development (230).

The receptor tyrosine kinases (RTK) are a promising target for developing specific therapies. This is a family of transmembrane glycoproteins that have a cytoplasmic tyrosine kinase domain, and the subfamilies include the human epidermal growth factor receptors (including HER2/neu) and the receptors for various growth factors that were previously described. Numerous RTK inhibitors are being evaluated in the clinic, including those that target platelet derived growth factor receptor (SU101, CGP57148, PD166285), epidermal growth factor receptor (ZD1839, CP358 774, CGP 59236), and the receptor for vascular endothelial growth factor, Flk-1/KDR (SU5416) (233, 234).

Some genetic expression properties of the breast cancer cell may be exploited for delivery of a toxic agent, enhancing tumor-specific immunity, or for mediating gene transfer. For example, a recent phase I clinical trial successfully used the cytosine deaminase gene driven by the human erbB-2 promoter to convert inactive fluorocytosine to active fluorouracil only in cells expressing ErbB-2 (235). Alternative epitopes expressed on tumors have been used for selective therapies. Recombinant vaccinia virus used in an experimental pulmonary metastasis model demonstrated that 90% of mice innoculated with the vaccine were protected from the development of metastasis (236). Other approaches include up regulating specific genes critical for normal cellular activity, while simultaneously suppressing or knocking out tumor-specific genes. p53 represents the most likely candidate and is currently being evaluated in phase I and phase II clinical trials. This approach has been limited however, by the rather poor ability of most vectors to efficiently deliver the desired gene into the tumor cell (237).


The cell cycle is a focus for studying cancer growth and progression since an underlying theme in human breast cancer and other cancers is enhanced cell cycle activity leading to unrestricted growth. With the identification and characterization of molecular determinants of normal growth, development and differentiation, and the application of this knowledge toward understanding the development of cancer, many aspects of oncogenesis and metastasis have been unraveled. The analysis of overexpressed gene products, growth factors, and other cellular agents stimulating cell proliferation and tumor growth has imparted some insight into the mechanisms of cancer formation. These insights have provided the basis for developing specific therapies that are targeted at interfering with particular biological processes. Transgenic mouse models have provided fundamental information that has substantially advanced our understanding of breast cancer mechanisms and therapeutics. Advances in the future will likely come in part through identifying genetic predisposition to tumor development through applying genomic array analysis technology (238). This technology will likely also be key in identifying important new therapeutics.


This work was supported by RO1CA70897 and RO1CA75503 (to R.G.P.). Work at the Albert Einstein College of Medicine is supported by the Albert Einstein Comprehensive Cancer Center (CA13330) and the Diabetes Research and Training Center (DK20541).


1. Greenlee R. T., T. Murray, S. Bolden, and P. A. Wingo: Cancer Statistics, 2000. CA Cancer J Clin 50, 7-33 (2000)

2. Dignam J. J.: Differences in breast cancer prognosis among African-American and Caucasian women. CA Cancer J Clin 50, 50-64 (2000)

3. Harris J. R., M. E. Lippman, U. Veronesi, and W. Willett: Breast cancer (Second of Three Parts) N Engl J Med 327, 390-393 (1992)

4. Rahman N., and M. R. Stratton: The genetics of breast cancer susceptibility. Annu. Rev. Genet. 32, 95-121 (1998)

5. Claus E. B., N. Risch, and W. D. Thompson: Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 48, 232-242 (1991)

6. Rebbeck T. R.: Inherited genetic predisposition in breast cancer. Cancer 86(11 Suppl), 2493-2501 (1999)

7. Struewing J. P., P. Hartge, S. Wacholder, S. M. Baker, M. Berlin, M. McAdams, M. M. Timmerman, L. C. Brody, and M. A. Tucker: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336, 1401-8 (1997)

8. Mancini D., Rodenhiser DI, Ainsworth PJ, O'Malley FP, Singh SM, X. W, and A. TK.: Oncogene 16, 1161-1169 (1998)

9. Catteau A., W. H. Harris, C. F. Xu, and E. Solomon: Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18, 1957-1965. (1999)

10. Wilson C. A., L. Ramos, M. R. Villasenor, K. H. Anders, M. F. Press, K. Clarke, B. Karlan, J. J. Chen, R. Scully, D. Livingston, R. H. Zuch, M. H. Kante, S. Cohen, F. J. Calzone, and D. J. Slamon: Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat. Genet. 21, 236-40 (1999)

11. Ford D., et al.: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast. Am J Hum Genet 62, 676-689 (1998)

12. Schuyer M., and E. M. Berns: Is TP53 dysfunction required for BRCA1-associated carcinogenesis? Mol Cell Endocrinol 155, 143-152 (1999)

13. Smith P., S. Crossland, G. Parker, P. Osin, L. Brooks, J. Waller, E. Philp, M. Crompton, B. Gusterson, M. Allday, and T. Crook: Novel p53 mutants selected in BRCA-associated tumors which dissociate transformation suppression from other wild-type p53 functions. Oncogene 18, 2451-2459 (1999)

14. Gowen L. C., B. L. Johnson, A. M. Latour, K. K. Sulik, and B. H. Koller: Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat. Genet. 12, 191-194 (1996)

15. Gowen L. C., A. V. Avrutskaya, A. M. Latour, B. H. Koller, and S. A. Leadon: BRCA-1 required for transcription-coupled repair of oxidative DNA damage. Science 281, 1009-1012 (1998)

16. Sharan S., M. Morimatsu, U. Albrecht, D. Lim, E. Regel, C. Dinh, A. Sands, G. Eichele, P. Hasty, and A. Bradley: Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386, 804-810 (1997)

17. Venkitaramin A. R.: Breast cancer genes and DNA repair. Science 286, 1100-1102 (1999)

18. Scully R., J. Chen, A. Plug, Y. Xiao, D. Weaver, J. Feunteun, T. Ashley, and D. Livingston: Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells. Cell 88, 265-275 (1997)

19. Cortez D., Y. Wang, J. Qin, and S. Elledge: Requirement of ATM-Dependent Phosphorylation of Brca1 in the DNA Damage Response to Double-Strand Breaks. Science 286, 804-810 (1999)

20. Scully R., J. Chen, R. L. Ochs, K. Keegan, M. Hoekstra, J. Feunteun, and D. M. Livingston: Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 90, 425-435 (1997)

21. Fan S., J.-A. Wang., R. Yuan, Y. Ma, Q. Meng, M. R. Erdos, R. G. Pestell, F. Yuan, K. J. Auborn, I. D. Goldberg, and E. M. Rosen: BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284, 1354-1356. (1999)

22. Fan S., Y. X. Ma, C. Wang, R.-q. Yuan, Q. Meng, J.-A. Wang., M. R. Erdos, I. D. Goldberg, P. Webb, P. J. Kushner, R. G. Pestell, and E. M. Rosen: Inhibition of estrogen receptor activity by a BRCA1:ER-a interaction. Oncogene In Press, (2000)

23. Maul G. G., D. E. Jensen, A. M. Ishov, M. Herlyn, and J. F. Rauscher: Nuclear redistribution of BRCA1 during viral infection. Cell. Growth. Differ. 9, 743-755 (1998)

24. Hakem R., J. L. de la Pompa, A. Elia, J. Potter, and T. W. Mak: Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. Nat. Genet. 16, 298-230 (1997)

25. Xu X., Z. Weaver, S. P. Linke, C. Li, J. Gotay, X.-W. Wang, C. C. Harris, T. Ried, and C.-X. Deng: Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol. Cell 389-395 (1999)

26. Crook T., L. A. Brooks, S. Crossland, P. Osin, K. T. Barker, J. Waller, E. Philp, P. D. Smith, I. Yulug, J. Peto, G. Parker, M. J. Allday, M. R. Crompton, and B. A. Gusterson: Oncogene 17, 1681-1689 (1998)

27. Phillips K. A., K. Nichol, H. Ozcelik, J. Knight, S. J. Done, P. J. Goodwin, and I. L. Andrulis: Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. J. Natl. Cancer. 91, 469-473 (1999)

28. Shen S. X., Z. Weaver, X. Xu, C. Li, M. Weinstein, L. Chen, X. Y. Guan, T. Ried, and C. X. Deng: Oncogene 17, 3115-3124 (1998)

29. Aprelikova O. N., B. S. Fang, E. G. Meissner, S. Cotter, M. Campbell, A. Kuthiala, M. Bessho, R. A. Jensen, and E. T. Liu: BRCA1-associated growth arrest is RB-dependent. Proc. Natl. Acad. Sci. USA 96, 11866-11871 (1999)

30. Shao N., Y. L. Chai, E. Shyam, P. Reddy, and V. N. Rao: Induction of apoptosis by the tumor suppressor protein BRCA1. Oncogene 13, 1-7 (1996)

31. Xu X., K. U. Wagner, D. Larson, Z. Weaver, C. Li, T. Ried, L. Hennighausen, A. Wynshaw-Boris, and C. X. Deng: Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 22, 37-43 (1999)

32. Lane T. F., C. Lin, M. A. Brown, E. Solomon, and P. Leder: Gene replacement with the human BRCA1 locus:tissue specific expression and rescue of embryonic lethality in mice. Oncogene 19, 4085-4090 (2000)

33. Hortobagyi G. N.: Treatment of breast cancer. N Eng J Med 339, 974-984 (1998)

34. Krag D., D. Weaver, T. Ashikaga, F. Moffat, V. S. Klimberg, C. Shriver, S. Feldman, R. Kusminsky, M. Gadd, J. Kuhn, S. Harlow, and P. Beitsch: The sentinel node in breast cancer: a multicenter validation study. N Eng J Med 941-946 (1998)

35. Dickson R. B., and M. E. Lippman: Growth factors in breast cancer. Endocr. Rev. 16, 559-589 (1995)

36. Sutherland M. C., and W. L. Macguire: Regulatory Mechanisms in Breast Cancer. Ed: Lippman, M., and Dickson, R., 3-22 (1991)

37. Sherr C. J.: Cancer cell cycles. Science 274, 1672-1677 (1996)

38. Motokura T., and A. Arnold: Cyclin D and oncogenesis. Curr. Opin. Genet. Dev. 3, 5-10 (1993)

39. Weinberg R. A.: The retinoblastoma protein and cell cycle control. Cell 81, 323-330 (1995)

40. Pestell R. G., C. Albanese, A. T. Reutens, J. E. Segall, R. J. Lee, and A. Arnold: The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocrine Rev. 20, 501-534 (1999)

41. Geng Y., W. Whoriskey, M. Y. Park, R. T. Bronson, R. H. Medema, T. Li, R. A. Weinberg, and P. Sicinski: Rescue of cyclin D1 deficiency by knockin cyclin E. Cell 97, 767-777 (1999)

42. Zhao J., B. Dynlacht, T. Imai, T. Hori, and E. Harlow: Expression of NPAT, a novel substrate of cyclin E-CDK2, promotes S-phase entry. Genes Dev. 12, 456-461 (1998)

43. Okuda M., H. F. Horn, P. Tarapore, Y. Tokuyama, P. Smulian, P.-K. Chan, E. S. Knudsen, I. A. Hofman, J. D. Snyder, K. E. Bove, and K. Fukasawa: Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 103, 127-140 (2000)

44. Krude T., M. Jackman, J. Pines, and R. A. Laskey: Cyclin/Cdk-dependent initiation of DNA replication in a human cell-free system. Cell 88, 109-119 (1997)

45. Ma T., B. A. Van Tine, Y. Wei, M. D. Garrett, D. Nelson, P. D. Adams, J. Wang, J. Qin, L. T. Chow, and J. W. Harper: Cell cycle-regulated phosphorylation of p220 NPAT by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. Genes and Dev. 14, 2298-2313 (2000)

46. Matsushime H., D. E. Quelle, S. A. Shurtleff, M. Shibuya, C. J. Sherr, and J.-Y. Kato: D-Type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol. 14, 2066-2076 (1994)

47. Sherr C. J., and J. M. Roberts: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes and Dev. 9, 1149-1163 (1995)

48. LaBaer J., M. D. Garrett, L. F. Stevenson, J. M. Slingerland, C. Sandhu, H. S. Chou, A. Fattaey, and E. Harlow: New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11, 847-862 (1997)

49. Cheng M., P. Olivier, J. A. Diehl, M. Fero, M. F. Roussel, J. M. Roberts, and C. J. Sherr: The p21Cip1 and p27Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 18, 1571-1583 (1999)

50. Sherr C. J., and J. M. Roberts: CDK inhibitors:positive and negative regulators of G1-phase progression. Genes and Dev. 13, 1501-1512 (1999)

51. Wang T. C., R. D. Cardiff, L. Zukerberg, E. Lees, A. Arnold, and E. V. Schmidt: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369, 669-671 (1994)

52. Lee R. J., C. Albanese, R. J. Stenger, G. Watanabe, G. Inghirami, G. K. I. Haines, M. Webster, W. J. Muller, J. S. Brugge, R. J. Davis, and R. G. Pestell: pp60v-src induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways: A role for cAMP response element-binding protein and activating transcription factor-2 in pp60v-src signaling in breast cancer cells. J. Biol. Chem 274, 7341-7350 (1999)

53. Lee R. J., C. Albanese, M. Fu, M. D'Amico, B. Lin, G. Watanabe, G. K. I. Haines, P. M. Siegel, M. C. Hung, Y. Yarden, J. M. Horowitz, W. J. Muller, and R. G. Pestell: Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol. Cell. Biol. 20, 672-683 (2000)

54. Albanese C., J. Johnson, G. Watanabe, N. Eklund, D. Vu, A. Arnold, and R. G. Pestell: Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J. Biol. Chem. 270, 23589-23597 (1995)

55. Westwick J. K., R. J. Lee, Q. T. Lambert, M. Symons, R. G. Pestell, C. J. Der, and I. P. Whitehead: Transforming potential of Dbl family proteins correlates with transcription from the cyclin D1 promoter but not with activation of Jun NH2-terminal kinase, p38/Mpk2, serum response factor, or c-Jun. J. Biol. Chem. 273, 16739-16747 (1998)

56. Westwick J. K., Q. T. Lambert, G. J. Clark, M. Symons, L. Van Aelst, R. G. Pestell, and C. J. Der: Rac regulation of transformation, gene expression and actin organization by multiple, PAK-independent pathways. Mol. Cell. Biol. 17, 1324-1335 (1997)

57. Coats S., W. M. Flanagan, J. Nourse, and J. M. Roberts: Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 272, 877-880 (1996)

58. Rivard N., G. L'Allemain, J. Bartek, and J. Pouysseacute;gur: Abrogation of p27Kip1 by cDNA antisense suppresses quiescence (G0 state) in fibroblasts. J. Biol. Chem. 271, 18337-18341 (1996)

59. Fero M. L., E. Randel, K. E. Gurley, J. M. Roberts, and C. J. Kemp: The murine p27Kip1 is haplo-insufficient for tumour suppression. Nature 396, 177-180 (1998)

60. Agrawal D., F. Dong, Y. Z. Wang, D. Kayda, and W. J. Pledger: Regulation of cyclin E and p27Kip during mitosis in Balb/c3T3 cells. Cell Growth Differ. 6, 1199-1205 (1995)

61. Winston J., F. Dong, and W. J. Pledger: Differential modulation of G1 cyclins and the Cdk inhibitor p27kip1 by platelet-derived growth factor and plasma factors in density- arrested fibroblasts. J. Biol. Chem. 271, 11253-11260 (1996)

62. Firpo E. J., A. Koff, M. J. Solomon, and J. M. Roberts: Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mol. Cell. Biol. 14, 4889-4901 (1994)

63. Sheaff R. J., M. Groudine, M. Gordon, J. M. Roberts, and B. E. Clurman: Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev. 11, 1464-1478 (1997)

64. Pagano M., S. W. Tam, A. M. Theodoras, P. Beer-Romero, G. Del Sal, V. Chau, P. R. Yew, G. F. Draetta, and M. Rolfe: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269, 682-685. (1995)

65. Latres E., D. S. Chiaur, and M. Pagano: The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. Oncogene 18, 849-854 (1999)

66. Lisztwan J., A. Marti, H. Sutterluty, M. Gstaiger, C. Wirbelauer, and W. Krek: Association of human CUL-1 and ubiquitin-conjugating enzyme CDC34 with the F-box protein p45(SKP2): evidence for evolutionary conservation in the subunit composition of the CDC34-SCF pathway. EMBO J 17, 368-383 (1998)

67. Yu Z. K., J. L. Gervais, and H. Zhang: Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc Natl Acad Sci USA 95, 11324-1329 (1998)

68. Chen J., P. K. Jackson, M. W. Kirschner, and A. Dutta: Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374, 386-388 (1995)

69. Goubin F., and B. Ducommun: Identification of binding domains on p21Cip1 cyclin-dependent kinase inhibitor. Oncogene 10, 2281-2287 (1995)

70. Nakanishi M., R. S. Robetorye, G. R. Adami, O. M. Pereira-Smith, and J. R. Smith: Identification of the active region of the DNA synthesis inhibitory gene p21Sdi1/CIP1/WAF1. EMBO J. 14, 555-563 (1995)

71. Chen J., P. Saha, S. Kornbluth, B. D. Dynlacht, and A. Dutta: Cyclin-binding motifs are essential for the function of p21CIP1. Mol. Cell. Biol. 16, 4673-4682 (1996)

72. Luo Y., J. Hurwitz, and J. Massagueacute;: Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 375, 159-161 (1995)

73. Warbrick E., D. P. Lane, D. M. Glover, and L. S. Cox: A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. Curr. Biol. 5, 275-282 (1995)

74. Flores-Rozas H., Z. Kelman, F. B. Dean, Z. Q. Pan, J. W. Harper, S. J. Eledge, M. O'Donnell, and J. Hurwitz: Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc. Natl. Acad. Sci. USA. 91, 8655-8659 (1994)

75. Zhang H., G. J. Hannon, and D. Beach: p21-containing cyclin kinases exist in both active and inactive states. Genes Dev. 8, 1750-1758 (1994)

76. Harper J. W., S. J. Elledge, K. Keyomarski, B. Dynlacht, L.-H. Tsai, P. Zhang, S. Dobrowolski, C. Bai, L. Connell-Crowley, E. Swindell, M. P. Fox, and N. Wei: Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell 6, 387-400 (1995)

77. Polyak K., J.-Y. Kato, M. J. Solomon, S. C.J., J. Massagueacute;, J. M. Roberts, and A. Koff: p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 8, 9-22 (1994)

78. Polyak K., M. H. Lee, H. Erdjument-Bromage, A. Koff, J. M. Roberts, P. Tempst, and J. Massagueacute;: Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78, 59-66 (1994)

79. Reynisdottir I., K. Polyak, A. Iavarone, and J. Massagueacute;: Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-szlig;. Genes Dev. 9, 1831-1845. (1995)

80. Soos T. J., H. Kiyokawa, J. S. Yan, M. S. Rubin, A. Giordano, A. DeBlasio, S. Bottega, B. Wong, J. Mendelsohn, and A. Koff: Formation of p27-CDK complexes during the human mitotic cell cycle. Cell Growth Differ. 7, 135-146 (1996)

81. Slamon D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987)

82. Zhou D., H. Battifora, J. Yokata, T. Yamamoto, and M. J. Cline: Association of multiple copies of the c-erbB-2 oncogene with the spread of breast cancer. Cancer Res. 47, 6123-6125 (1987)

83. Borresen A.-L., L. Ottestad, A. Gaustad, T. I. Anderson, R. Heikkila, T. Jahnsen, K. M. Tveit, and J. M. Nesland: Amplification and protein over-expression of the neu/HER-2/c-erbB-2 proto-oncogene in human breast carcinomas: relationship to loss of gene sequence on chromosome 17, family history, and prognosis. Br J Cancer 62, 585-590 (1990)

84. Varley J. M., J. E. Swallow, W. J. Brammar, J. L. Whittaker, and R. A. Walker: Alterations to either c-erbB-2 (neu) of c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1, 423-430 (1987)

85. Jardines L., M. Weiss, B. Fowble, and M. Greene: neu (c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology. 61, 268-282 (1993)

86. Lacroix H., J. D. Iglehart, M. A. Skinner, and M. H. Kraus: Overexpression of erbB-2 or EGF-receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastasis. Oncogene 4, 145-151 (1989)

87. Peles E., and Y. Yarden: Neu and its ligands: from an oncogene to neural factors. BioEssays 15, 815-824 (1993)

88. Pinkas-Kramarski R., L. Soussan, H. Waterman, G. Levkowitz, I. Alroy, L. Klapper, S. Lavi, R. Seger, B. J. Ratzkin, M. Sela, and Y. Yarden: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 15, 2452-2467 (1996)

89. Janes P. W., R. J. Daly, A. deFazio, and R. L. Sutherland: Activation of the Ras signaling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 9, 3601-3608 (1994)

90. Muthuswamy S. K., P. M. Siegel, D. L. Dankort, M. A. Webster, and W. J. Muller: Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol. Cell. Biol. 14, 735-743 (1994)

91. Qian X., W. C. Dougall, Z. Fei, and M. I. Greene: Intermolecular association and trans-phosphorylation of different neu-kinase forms permit SH2-dependent signaling and oncogenic transformation. Oncogene 10, 211-219 (1995)

92. Bargmann C. I., M.-C. Hung, and R. A. Weinberg: Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45, 649-657 (1986)

93. Guy C. T., M. A. Webster, M. Schaller, T. J. Parson, R. D. Cardiff, and W. J. Muller: Expression of the neu proto-oncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 89, 10578-10582 (1992)

94. Muller W. J., E. Sinn, P. K. Pattengale, R. Wallace, and P. Leder: Single step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54, 105-115 (1988)

95. Siegel P. M., D. L. Dankort, W. R. Hardy, and W. J. Muller: Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol. Cell. Biol. 14, 7068-7077 (1994)

96. Escot C., C. Theillet, R. Lidereau, F. Spyratos, M. H. Champeme, J. Gest, and R. Callahan: Genetic alteration of the c-myc proto-oncogene in human primary breast carcinomas. Proc. Natl. Acad. Sci. USA 83, 4834-4838 (1986)

97. Bonilla M., M. Ramirez, J. Lopez-Cuento, and P. Gariglio: In vivo amplification and rearrangement of c-myc oncogene in human breast tumors. J. Natl. Cancer Inst. 80, :665-671 (1988)

98. Cline M., H. Battifora, and J. J. Yokota: Protooncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of diagnosis. J. Clin. Oncol. 5, 999-1006 (1987)

99. Varlay J. M., J. E. Swallow, V. J. Brammer, J. L. Wittaker, and R. A. Waekor: Alterations to either c-erb2 (neu) short term prognosis. Oncogene 1, 423-430 (1987)

100. Evan G. I., A. H. Wyllie, C. S. Gilbert, T. D. Littlewood, H. Land, M. Brooks, C. M. Waters, L. Z. Penn, and D. C. Hancock: Induction of apoptosis in fibroblasts by c-myc protein. Cell 69, 119-28 (1992)

101. Watson P. H., R. T. Pon, and R. P. Shiu: Inhibition of c-myc expression by phosphothorioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Research 51, 3996-4000 (1991)

102. Stewart T. A., P. K. Pattengale, and P. Leder: Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MMTV/myc fusion genes. Cell 38, 627-637 (1984)

103. Sinn E., W. Muller, P. Pattengale, I. Tepler, R. Wallace, and P. Leder: Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 49, 465-475 (1987)

104. Morrison B. W., and P. Leder: neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. Oncogene 3417-3426 (1994)

105. Amati B., T. D. Littlewood, G. I. Evan, and H. Land: The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J. 12, 5083-5087 (1993)

106. Galaktionov K., X. Chen, and D. Beach: Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 382,, 511-517 (1996)

107. Zindy F., C. M. Eischen, D. H. Randle, T. Kamijo, J. L. Cleveland, C. J. Sherr, and M. F. Roussel: Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12, 2424-2433 (1998)

108. Vlach J., S. Hennecke, K. Alevizopoulis, D. Conti, and B. Amati: Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J. 15, 6595-6604 (1996)

109. Leone G., J. Degregori, R. Sears, L. Jakoi, and J. R. Nevins: Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 387, 422-426 (1997)

110. Rustgi A. K., N. Dyson, and R. Bernards: Amino terminal domains of c-myc and N-myc proteins mediate binding to the retinoblastoma gene product. Nature 352, 541-544 (1991)

111. Perez-Roger I., S.-H. Kim, B. Griffiths, A. Sewing, and H. Land: Cyclins D1 and D2 mediate Myc-induced proliferation via sequestration of p27Kip1 and p21Cip1. EMBO J. 18, 5310-5320 (1999)

112. Rudolph B., R. Saffrich, J. Zwicker, B. Henglein, R. Muller, W. Ansorge, and M. Eilers: Activation of cyclin-dependent kinases by Myc mediates induction of cyclin A, but not apoptosis. EMBO J. 15, 3065-3076 (1996)

113. Penn L. J., E. M. Laufer, and H. Land: C-MYC: evidence for multiple regulatory functions. Semin. Cancer Biol. 1, 69-80 (1990)

114. Feig L. A., and G. M. Cooper: Inhibition of NIH3T3 cell proliferation by a mutant Ras protein with preferential affinity for GDP. Mol. Cell. Biol. 8, 3235-3243 (1988)

115. O'Neill E. M., I. Rebay, R. Tjian, and G. M. Rubin: The activities of two Ets-related transcription factors are required for drosophila eye development are modulated by the ras/MAPK pathway. Cell 78, 135-147 (1994)

116. Feig L. A.: The many roads that lead to Ras. Science 260, 767-768 (1993)

117. Boguski M. S., and F. McCormick: Proteins regulating Ras and its relatives. Nature 366, 643-654 (1993)

118. McCormick F.: How receptors turn Ras on. Nature 363, 15-16 (1993)

119. Zipursky S. L., and G. M. Rubin: Determination of neuronal cell fate:lessons from the R7 neuron of drosophila. Annu. Rev. Neurosci. 17, 373-397 (1994)

120. Theillet C., R. Liderau, C. Escot, P. Hutzell, M. Brunet, J. Gest, J. Schlom, and R. Callahan: Loss of c-H-ras-1 allele and aggressive human primary breast carcinoma. Cancer Res. 46, 4776-4781 (1986)

121. Hulit J., T. Bash, M. Fu, F. Galbiati, C. Albanese, D. R. Sage, A. Schlegel, J. Zhurinsky, M. Shtutman, A. Ben-Ze'ev, M. P. Lisanti, and R. G. Pestell: The cyclin D1 gene is transcriptionally repressed by caveolin-1. J. Biol. Chem. 275, 21203-21209 (2000)

122. Engelman J. A., R. J. Lee, A. Karnezis, D. J. Bearss, M. Webster, P. Siegel, W. J. Muller, J. J. Windle, R. G. Pestell, and M. P. Lisanti: Reciprocal regulation of Neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo: Implications for human breast cancer. J. Biol. Chem. 273, 20448-20455 (1998)

123. Lavoie J. N., G. L'Allemain, A. Brunet, R. Muuml;ller, and J. Pouysseacute;gur: Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J. Biol. Chem. 271, 20608-20616 (1996)

124. Robles A. I., M. L. Rodriguez-Puebla, A. B. Glick, C. Trempus, L. Hansen, P. Sicinski, R. W. Tennant, R. A. Weinbergh, S. H. Yuspa, and C. J. Conti: Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev. 12, 2469-2474 (1998)

125. Collett M. S., A. F. Purchio, and R. L. Erikson: Avian sarcoma virus-transforming protein pp60src shows protein kinase activity specific for tyrosine. Nature 285, 167-169 (1980)

126. Hanafusa H. Cell transformation by RNA tumor viruses. In Comprehensive Virology. Fraenkel-Conrat H., and R.P. Wagner, Fraenkel-Conrat H., and R.P. Wagners. Plenum, New York. 401-483. (1977)

127. Ottenhoff-Kalff A. E., G. Rijksen, E. A. C. M. van Beurden, A. Hennipman, A. A. Michels, and G. E. J. Staal: Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res. 52, 4773-4778 (1992)

128. Webster M. A., R. D. Cardiff, and W. J. Muller: Induction of mammary epithelial hyperplasias and mammary tumors in transgenic mice expressing a murine mammary tumor virus/activated c-src fusion gene. Proc. Natl. Acad. Sci. USA 92, 7849-7853 (1995)

129. Liu J.-J., J.-R. Chao, M.-C. Jiang, S.-Y. Ng, J. J.-Y. Yen, and H.-F. Yang-Yen: Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH3T3 cells. Mol. Cell. Biol. 15, 3654-3663 (1995)

130. Muthuswamy S. K., and W. J. Muller: Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor. Oncogene 11, 271-279 (1995)

131. Sheffield L.: c-Src activation by ErbB-2 leads to attachment-independent growth of human breast epithelial cells. Biochem Biophys Res Commun 250, 27-31 (1998)

132. Rahimi N., W. Hung, E. Tremblay, R. Saulnier, and B. Elliott: c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent. J. Biol. Chem. 273, 33714-33721 (1998)

133. Karni R., R. Jove, and A. Levitzki: Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene 18, 4654-4662 (1999)

134. Mukhopadhyay D., L. Tsiokas, X. Zhou, D. Foster, J. Brugge, and V. Sukhatme: Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375, 577-581 (1995)

135. Roberts A. B. and Sporn, M.B.: The transforming growth factor-betas. In: Peptide Growth Factors and their Receptors. Ed. M.B. Sporn and A.B. Roberts. 419-472 (1990)

136. Markowitz S., J. Wang, L. Myeroff, R. Parsons, L. Sun, J. Lutterbaugh, R. S. Fan, E. Zborowska, K. W. Kinzler, and e. a. Vogelstein B: Inactivation of the type II TGFb receptor in colon cancer cells with microsatellite instability. Science 268, 1336-1338 (1995)

137. Markowitz S. D., and A. B. Roberts: Tumor suppressor activity of the TGFb pathway in human cancers. Cytokine Growth Factor Review 1, 93-102 (1996)

138. Bottinger E. P., J. J. Letterio, and A. B. Roberts: Biology of TGF-beta in knockout and transgenic mouse models. Kidney Int . 51, 1355-1360 (1997)

139. Hahn S. A., M. Schutte, A. T. Hoque, C. A. Moskaluk, L. T. da Costa, E. Rozenblum, C. L. Weinstein, A. Fischer, C. J. Yeo, R. H. Hruban, and S. E. Kern: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271, 350-353 (1996)

140. Dickson R. B., and M. E. Lippman: Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocrine Reviews 8, 29-43 (1987)

141. Paul D., and G. H. Schmidt: Immortalization and malignant transformation of differentiated cells by oncogenes in vitro and in transgenic mice. Crit. Rev. Oncogenesis 1, 307-321 (1989)

142. Heldin C. H., and B. Westermark: Growth factors: mechanism of action and relations to oncogenes. Cell 37, 9-20 (1984)

143. Goustin A. S., E. B. Leof, G. D. Shipley, and H. L. Moses: Growth factors and cancer. Cancer Res. 46, 1015-1029 (1986)

144. Wakefield L. M., A. A. Colletta, B. K. Maccune, and M. B. Sporn, ed., Genes, Oncogenes, and Hormones., Boston: Kluwer, 97-130 (1992)

145. Sairenji M., K. Suzuki, K. Murakami, H. Motohashi, T. Okamoto, and M. Umeda: Transforming growth factor activity in pleural and peritoneal effusions from cancer and non-cancer patients. Jpn. J. Cancer Res. 78, 814-818 (1987)

146. McCure B. K., B. R. Mullin, K. C. Flanders, W. J. Jaffurs, L. T. Muller, and M. B. Sporn: Localization of transforming growth factor- isotypes in lesions of the human breast. Hum. Pathol. 23, 13-20 (1991)

147. Travers M. T., P. J. Barrett-Lee, U. Berger, Y. A. Luqmani, J.-C. Gazet, T. J. Powles, and R. C. Coombes: Growth factor expression in normal, benign, and malignant breast tissue. Br. Med. J. 296, 1621-1624 (1988)

148. Wu R. Y., Y. Zhang, X. H. Feng, and R. Derync: Heteromeric and homomeric interactions correlate with signaling activity and functional cooperativity of Smad3 and Smad4/DPC4. Mol. Cell. Biol. 17:, 2521-2528 (1997)

149. Derynck R., Y. Zhang, and X.-H. Feng: Smads:transcriptional activators of TGF-b responses. Cell 95, 737-740 (1998)

150. Zawel L., J. L. Dai, P. Buckhaults, S. Zhou, K. W. Kinzler, B. Vogelstein, and S. E. Kern: Human Smad3 and Smad4 are Sequence-Specific Transcription Activators. Molecular Cell 1, 611-7 (1998)

151. Iavarone A., and J. Massague: Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15. Nature 387, 417-422 (1997)

152. Jinno S., K. Suto, A. Nagata, M. Igarashi, Y. Kanaoka, H. Nojima, and H. Okayama: Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J 13, 1549-1556 (1994)

153. Galaktionov K., A. K. Lee, J. Eckstein, G. Draetta, J. Meckler, M. Loda, and D. Beach: CDC25 phosphatase as potential human oncogenes. Science 269, 1575-1577 (1995)

154. Bouzahzah B., M. Fu, A. Iaavarone, V. M. Factor, S. S. Thorgeirsson, and R. G. Pestell: Transforming growth factor b1 recruits histone deacetylase 1 to a p130 repressor complex in trangenic mice in vivo. Cancer Res. 60, 4531-4537 (2000)

155. Hassig C. A., J. K. Tong, T. C. Fleischer, T. Owa, P. G. Grable, D. E. Ayer, and S. L. Schreiber: A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. Proc Natl Acad Sci USA 95, 3519-3524 (1998)

156. Saito A., T. Yamashita, and Y. e. a. Mariko: A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA 96, 4592-4597 (1999)

157. Richon V. M., S. Emiliani, E. Verdini, and e. al.: A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci.USA 95, 3003-3007 (1998)

158. Saunders N. A., C. Popa, M. M. Serewko, S. J. Jones, A. J. Dicker, and A. L. Dahler: Histone deacetylase inhibitors: novel anticancer agents. Exp. Opin. Invest. Drugs 8, 1611-1621 (1999)

159. Lippman M., G. Bolan, and K. Huff: The effects of estrogens and antiestrogens on hormone responsive human breast cancer in long term tissue culture. Cancer Res. 36, 4595-4601 (1976)

160. Lippman M., and G. Bolan: Oestrogen-responsive human breast cancer in long term tissue culture. Nature 256, 592-593 (1975)

161. Leung B. S., and A. H. Potter: Mode of estrogen action on cell proliferation in CAMA-1 cells:II. Sensitivity of G1 phase population. J. Cell. Biochem. 34, 213-225 (1987)

162. Foster J. S., and J. Wimalasena: Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Molec. Endocrinol. 10, 488-498 (1996)

163. Altucci L., R. Addeo, L. Cicatiello, S. Dauvois, M. G. Parker, M. Truss, M. Beato, V. Sica, F. Bresciani, and A. Weisz: 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 12, 2315-2324 (1996)

164. Musgrove E. A., B. Sarcevic, and R. L. Sutherland: Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for Cdk2 activation and pRB hyperphosphorylation. J. Cell. Biochem. 60, 363-78 (1996)

165. Musgrove E. A. Sutherland, R.L.: Steroids, growth factors, and cell cycle controls in breast cancer. Cancer Treat. Res. 53, 305-331 (1991)

166. Musgrove E. A. Lee, C.S., Sutherland, R.L.: Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol. Cell. Biol. 11, 5032-5043 (1991)

167. Musgrove E. A. and Sutherland, R.L: Effects of the progestin antagonist RU486 on T-47D cell proliferation. Biophys. Biochem. Res. Comm. 195, 1184-1190 (1993)

168. Horwitz K. B.: The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer ? Endocr. Rev. 13, 146-163 (1992)

169. Davis V. L., J. F. Couse, E. H. Goulding, S. G. Power, E. M. Eddy, and K. S. Korach: Aberrant reproductive phenotypes evident in transgenic mice expressing the wild-type mouse estrogen receptor. Endocrinology 135, 379-86 (1994)

170. Korach K. S., J. F. Couse, S. W. Curtis, T. F. Washburn, J. Lindzy, K. S. Kimbro, E. M. Eddy, S. Migliaccio, S. M. Snedeker, D. B. Lubahn, D. W. Schomberg, and E. P. Smith: Estrogen receptor gene disruption:molecular characterization and experimental and clinical phenotypes. Recent Prog. Horm. Res. 51, 159-186 (1996)

171. Johns A., A. D. Freay, W. Fraser, K. S. Korach, and G. M. Rubanyi: Disruption of estrogen receptor gene prevents 17 beta estradiol-induced angiogenesis in transgenic mice. Endocrinology 137, 4511-4513 (1996)

172. Eddy E. M., T. F. Washburn, D. O. Bunch, E. H. Goulding, B. C. Gladen, D. B. Lubahn, and K. S. Korach: Targeted disruption of the estrogen receptor gene in male mice causes alteration of spermatogenesis and infertility. Endocrinology 137, 4796-805 (1996)

173. Beato M.: Gene regulation by steroid hormones. Cell 56, 335-344 (1989)

174. Truss M. and Beato, M.: Steroid hormone receptors:Interaction with deoxyribonucleic acid and transcription factors. Endocrine Reviews 14, 459-479 (1993)

175. Migliaccio A., M. DiDomenico, G. Castoria, A. deFalco, P. Bontempo, E. Nola, and F. Auricchio: Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J. 15, 1292-1300 (1996)

176. Ignar-Trowbridge D. M., M. Pimentel, M. G. Parker, J. A. McLachlan, and K. S. Korach: Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology 137, 1735-1744 (1996)

177. Schuchard M., J. P. Landers, N. P. Sandhu, and T. C. Spelsberg: Steroid hormone regulation of nuclear proto-oncogenes. Endocrine Reviews 14, 659-669 (1993)

178. Sumi-Ichinose C., H. Ichinose, D. Metzger, and P. Chambon: SNF2beta-BRG1 is essential for the viability of F9 murine embryonal carcinoma cells. Mol. Cell. Biol. 17, 5976-5986 (1997)

179. Mengus G., M. May, L. Carre, P. Chambon, and I. Davidson: Human TAF(II)135 potentiates transcriptional activation by the AF-2s of the retinoic acid, vitamin D3, and thyroid hormone receptors in mammalian cells. Genes Dev. 11, 1381-1395 (1997)

180. Le Douarin B., A. L. Nielsen, J. M. Garnier, H. Ichinose, F. Jeanmougin, R. Losson, and P. Chambon: A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors. EMBO J. 15:, 6701-15 (1996)

181. O'Malley B. W.: Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog. Horm. Res. 52, 141-164 (1997)

182. Tsihlias J., L. Kapusta, and J. Slingerland: The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu. Rev. Med. 50, 401-423 (1999)

183. Kenny F. S., R. Hui, E. A. Musgrove, J. M. Gee, R. W. Blamey, R. I. Nicholson, R. L. Sutherland, and J. F. Robertson: Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin. Cancer Res. 5, 2069-2076 (1999)

184. Musgrove E. A., J. A. Hamilton, C. S. L. Lee, K. J. E. Sweeney, C. K. W. Watts, and R. L. Sutherland: Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol. Cell. Biol. 13, 3577-3587 (1993)

185. Zwijsen R. M. L., E. Wientjens, R. Klompmaker, J. van der Sman, R. Bernards, and R. J. A. M. Michalides: CDK-independent activation of estrogen receptor by cyclin D1. Cell 88, 405-415 (1997)

186. Neuman E., M. H. Ladha, N. Lin, T. M. Upton, S. J. Miller, J. DiRenzo, R. G. Pestell, P. W. Hinds, S. F. Dowdy, M. Brown, and M. E. Ewen: Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol. Cell. Biol. 17, 5338-5347 (1997)

187. Zwijsen R. M. L., R. S. Buckle, E. M. Hijmans, C. J. M. Loomans, and R. Bernards: Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes and Dev. 12, 3488-3498 (1998)

188. Heery D. M., E. Kalkhoven, S. Hoare, and M. G. Parker: A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387, 733-736 (1997)

189. Trowbridge J. M., I. Rogatsky, and M. J. Garabedian: Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. Proc. Natl. Acad. Sci. USA. 94, 10132-10137 (1997)

190. Couse J. F., J. Lindzey, K. Grandien, J. A. Gustafsson, and K. S. Korach: Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. Endocrinology 138, 4613-4621 (1997)

191. Paech K., P. Webb, G. G. Kuiper, S. Nilsson, J. Gustafsson, P. J. Kushner, and T. S. Scanlan: Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277, 1508-1510 (1997)

192. Lukas J., J. Bartkova, and J. Bartek: Convergence of mitogenic signaling cascades from diverse classes of receptors at the cyclin D-cyclin dependent kinase-pRb-controlled G1 checkpoint. Mol. Cell. Biol. 16, 6917-6925 (1996)

193. Planas-Silva M. D., and R. A. Weinberg: Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol. Cell. Biol. 17, 4059-4069 (1997)

194. Prall O. W. J., B. Sarcevic, E. A. Musgrove, C. K. W. Watts, and R. L. Sutherland: Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E- Cdk2. J. Biol. Chem. 272, 10882-10894 (1997)

195. Prall O. W. J., E. M. Rogan, E. A. Musgrove, C. K. W. Watts, and R. L. Sutherland: c-Myc or cyclin D1 mimics estrogen effects on cyclin E-cdk2 activation and cell cycle reentry. Mol. Cell. Biol. 18, 4499-4508 (1998)

196. Heffelfinger S. C., M. A. Miller, R. Yassin, and R. Gear: Angiogenic growth factors in preinvasive breast disease. Clin Cancer Res 5, 2867-2876 (1999)

197. Engels K., S. Fox, R. Whitehouse, K. Gatter, and A. Harris: Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast. J Pathol 181, 207-212 (1997)

198. Folkman J., and Y. Shing: Angiogenesis. J Biol Chem 267, 10931-10934 (1992)

199. Tilsty T. D., A. L. White, and J. Sanchez: Suppression of gene amplification in human cell hybrids. Science 256, 1425-1427 (1992)

200. van der Burg B., R. Slager-Davidov, M. van der Leede B-j, S. W. de Laat, and P. T. van der Saag: Differential regulation of AP1 activity by retinoic acid in hormone-dependent and -independent breast cancer cells. Mol. and Cell. Endocrinol. 112, 143-152 (1995)

201. Sgroi D., S. Teng, G. Robinson, R. LeVangie, J. J. Hudson, and A. Elkahloun: In vivo gene expression profile analysis of human breast cancer progression. Cancer Res. 59, 5656-5661 (1999)

202. Nicolson G. L., and A. S. Moustafa: Metastasis-Associated genes and metastatic tumor progression. In Vivo 12, 579-588 (1998)

203. Liotta L. A., P. S. Steeg, and W. G. Stetler-Stevenson: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64, 327-336 (1991)

204. Ebralidze A., E. Tilchinsky, M. Grigorian, A. Afanasyeva, V. Senin, E. Revasova, and E. Lukanidin: Isolation and characterization of a gene specifically expressed in different metastatic cells and whose deduced gene product has a high degree of homology to a Ca2+-binding protein family. Genes Dev 3, 1086-1093 (1989)

205. Steeg P. S.: Search for metastasis suppressor genes. Invasion Metastasis 9, 351-359 (1988)

206. Dear T. N., I. A. Ramshaw, and R. F. Kefford: Differential expression of a novel gene, WDNM1, in nonmetastatic rat mammary adenocarcinoma cells. Cancer Res. 48, 5203-5209 (1989)

207. Phillips S. M., A. J. Bendall, and I. A. Ramshaw: Isolation of gene associated with high metastatic potential in rat mammary adenocarcinomas. J. Natl. Cancer Inst. 82, 199-203 (1990)

208. Basset P., J. P. Bellocq, C. Wplf, I. Stoll, P. Hutin, J. M. Limacher, O. L. Podhajcer, M. P. Chenard, M. C. Rio, and P. Chambon: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348, 699-704 (1990)

209. Toh Y., S. D. Pencil, and G. L. Nicolson: A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. J. Biol. Chem. 269, 22958-22963 (1994)

210. Saphner T., D. C. Tormey, and R. G. Gray: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14, 2738-2746 (1996)

211. Group. E. B. C. T. C.: Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet. 930-942 (1998)

212. Mani S., C. Wang, R. Francis, and R. G. Pestell: Cyclin-dependent kinase inhibitors: novel anti-cancer drugs. Exp. Opin. Invest. Drugs, 9, 1849-1870 (2000)

213. Senderowicz A. M., D. Headlee, R. Lush, and e. al.: Phase I trial of infusional UCN-01, a novel protein kinase inhibitor, in patients with refractory neoplasms. Proc Am Soc Clin Oncol 18, (abstr 612) (1999)

214. Senderowicz A. M., D. Headlee, S. F. Stinson, R. M. Lush, N. Kalil, L. Villalba, K. Hill, S. M. Steinberg, W. D. Figg, A. Tompkins, S. G. Arbuck, and E. A. Sausville: Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16, 2986-2999 (1998)

215. Cobleigh M., C. L. Vogel, D. Tripathy, R. N.J., S. Scholl, L. Fehrenbacher, J. M. Wolter, V. Paton, S. Shak, G. Lieberman, and D. J. Slamon: Multinational study of the efficacy and safety of humanized monoclonal anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17, 2639-2648 (1999)

216. Slamon D., B. Leyland-Jones, S. Shak, et. al.: Addition of Herceptintrade; (humanized anti-her2 antibody) to first line chemotherapy for her2 overexpressing metastatic breast cancer markedly increased anticancer activity: a randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 17, abstr 377 (1998)

217. Sliwkowski M. X., J. A. Lofgren, G. D. Lewis, T. E. Hataling, B. M. Fendly, and J. A. Fox: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) Sem Oncol 26, 60-70 (1999)

218. Sparano J. A.: Cardiac toxicity of Herceptin: implications for the design of adjuvant trials. Sem Oncol (In Press)(2000)

219. Bissery M. C., G. Nohynek, G. J. Sandernink, and F. Lavette: Docetaxel: a review of preclinical and clinical experience. Part I: clinical experience. Anti-Cancer Drugs. 6, 1943-1951 (1995)

220. Haldar S., J. Chintapalli, and C. Croce: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56, 1253-1255 (1996)

221. Belotti D., V. Vergani, T. Drudis, et. al.: The microtubule drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 2, 1843-1849 (1996)

222. Verschueren H., J. Dewit, J. DeBraekeller, V. Schirrmacher, and P. DeBaetsleier: Motility and invasive potency of murine T-lymphoma cells: effect of microtubules inhibitors. Cell Biol Int. 11-19 (1994)

223. Stracke M. L., M. Soroush, L. A. Liotta, and E. Schiffman: Cytoskelatal agents inhibit motility and adherence of human tumor cells. Kidney Int. 43, 151-157, (1993)

224. Henderson I. C., D. Berry, G. Demetri, and e. al.: Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc Am Soc Clin Oncol 17, (abstr 390a)(1998)

225. Nelson A. R., B. Fingleton, M. L. Rothenberg, and L. M. Matrisian: Matrix metalloproteinases: biological activity and clinical implications. J Clin Oncol 18, 1135-1149 (2000)

226. Nemunaitis J., C. Poole, J. Primrose, and et. al.: Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selectin of a biologically active and tolerabel dose for longer-term studies. Clin Cancer Res 4, 1101-1109 (1998)

227. Dezube B. J., J. H. Von Roenn, J. Holden-Wiltse, T. W. Cheung, and e. al.: Fumagillin analog (TNP-470) in the treatment of Kaposiiacute;s sarcoma: a phase I AIDS Clinical Trials Group trial. J Clin Oncol 16, 1444-1449 (1998)

228. Fife K., M. R. Howard, F. Gracie, R. H. Phillips, et. al..: Activity of thalidomide in AIDS-related Kaposiiacute;s sarcoma and correlation with HHV8 titre. Intl J STD amp; AIDS 9, 751-755 (1998)

229. Baidas S. M., E. P. Winer, G. F. Fleming, L. Harris, J. M. Pluda, J. G. Crawford, H. Yamauchi, C. Isaacs, J. Hanfelt, M. Tefft, D. Flockhart, M. D. Johnson, M. J. Hawkins, M. E. Lippman, and D. F. Hayes: Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 18, 2710-2717 (2000)

230. Rowinsky E. K., J. J. Windle, and D. D. Von Hoff: Ras Protein Faarnesyltraansferase: a strategic target for anticancer therapeutic development. J Clin Oncol 17, 3631-3652 (1999)

231. Mangues R., T. Corral, N. E. Kohl, W. F. Symmans, S. Lu, M. Malumbres, J. B. Gibbs, A. Oliff, and A. Pellicer: Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res 58, 1253-1259 (1998)

232. Lebowitz P. F., and G. C. Prendergast: Non-ras targets for farnesyltransferase inhibitors: focus on Rho. 17, 1439-1447 (1998)

233. Hudes G.: Signaling inhibitors in the clinic: new agents and new challenges. J Clin Oncol 17, (1999)

234. Cherrington J. M., L. M. Strawn, and L. K. Shawver: New paradigms for the treatment of cancer: the role of anti- angiogenesis agents. Adv Cancer Res 79, 1-38 (2000)

235. Pandha H. S., L. Martin, A. Rigg, H. Hurst, G. Stamp, K. Sikora, and N. Lemoine: Genetic Prodrug Activation Therapy for Breast Cancer: A Phase I Clinical Trial of erbB-2-Directed Suicide Gene Expression. J. Clin. Oncol. 17, 2180-2189 (1999)

236. Akagi J., J. W. Hodge, J. P. McLaughlin, L. Gritz, G. Mazzara, D. Kufe, J. Schlom, and J. A. Kantor: Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. J. Immunotherapy 20, 38-47 (1997)

237. Gurnani M., P. Lipari, J. Dell, B. Shi, and L. Nielsen: Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother Pharmacol 44, 143-151 (1994)

238. Wang C., R. Francis, S. Harirchian, D. Batlle, B. Mayhew, M. Bassett, W. E. Rainey, and R. G. Pestell: The Application of High Density Microarray for Analysis Of Mitogenic Signaling and Cell-Cycle In the Adrenal. Endocr. Res. In Press, (2000)

239. Matsuoka M., J.-Y. Kato, R. P. Fisher, D. O. Morgan, and C. J. Sherr: Activation of cyclin-dependent kinase-4 (cdk4) by mouse MO15-associated kinase. Mol. Cell. Biol. 14, 7265-7275 (1994)

240. Toyoshima H., and T. Hunter: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78, 67-74 (1994)

241. Reynisdottir I., and J. Massagueacute;: The subcellular locations of p15Ink4b and p27Kip1 coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev. 11, 492-503 (1997)

242. Yang H. Y., B. P. Zhou, M. C. Hung, and M. H. Lee: Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. J Biol Chem 275, 24735-24739 (2000)

243. Zhou B. P., M. C. Hu, S. A. Miller, Z. Yu, W. Xia, S. Y. Lin, and M. C. Hung: HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 275, 8027-8031 (2000)

244. Siegel P. M., E. D. Ryan, R. D. Cardiff, and W. J. Muller: Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J. 18, 2149-2164 (1999)

245. Guha U., J. Hulit, and R. G. Pestell: Transgenic Mice in Cancer Research,. Encyclopedia of Cancer Second Edition, Ed. Bertino. J. Academic Press In Press, (2000)

246. Tsukamoto A. S., R. Grosschedl, R. C. Guzman, T. Parslow, and H. E. Varmus: Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 18, 619-625 (1988)

247. Lane T. F., and P. Leder: Wnt-10b directs hypermorphic development and transformation in mammary glands of male and female mice. Oncogene 15, 2133-2144. (1997)

248. Gallahan D., C. Jhappan, G. Robinson, L. Hennighausen, R. Sharp, E. Kordon, R. Callahan, G. Merlino, and G. H. Smith: Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. Cancer Res. 56, 1775-1785. (1996)

249. Smith G. H., D. Gallahan, F. Diella, C. Jhappan, G. Merlino, and R. Callahan: Constitutive expression of a truncated INT3 gene in mouse mammary epithelium impairs differentiation and functional development. Cell. Growth. Differ. 6, 563 -577 (1995)

250. Guy C. T., R. D. Cardiff, and W. J. Muller: Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic model for metastatic disease. Mol. Cell. Biol. 12, 954-961 (1992)

251. Jager R., U. Herzer, J. Schenkel, and H. Weiher: Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice. Oncogene 15, 1787-1795 (1997)

252. Donehower L. A., M. Harvey, B. L. Slagle, M. J. McArthur, C. A. J. Montgomery, J. S. Butel, and A. Bradley: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221 (1992)

253. Li B., J. M. Rosen, J. McMenamin-Balano, W. J. Muller, and A. S. Perkins: neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice. Mol. Cell. Biol. 17, 3155-3163 (1997)

254. Furth P. A., U. BarPeld, M. G. Li, A. Lewis, R. Laucirica, R. Jager, H. Weiher, and R. G. Russell: Loss of anti-mitotic effects of Bcl-2 with retention of anti-apoptotic activity during tumor progression in a mouse model. Oncogene 18, 6589 -6596 (1999)

255. Husler M. R., K. A. Kotopoulis, J. P. Sundberg, B. J. Tennent, S. V. Kunig, and B. B. Knowles: Transgenic. Res. 7, 253-263 (1998)

256. Tzeng Y. J., E. Guhl, M. Graessmann, and A. Graessmann: Oncogene 8, 1965-1971 (1993)

257. Joseph H., A. E. Gorska, P. Sohn, H. L. Moses, and R. Serra: Overexpression of a kinase-deficient transforming growth factor-beta type II receptor in mouse mammary stroma results in increased epithelial branching. Mol. Biol. Cell. 10, 1221-1234 (1999)

258. Iwamoto T., M. Takahashi, M. Ito, M. Hamaguchi, K. Isobe, N. Misawa, J. Asai, T. Yoshida, and I. Nakashima: Oncogenicity of the ret transforming gene in MMTV/ret transgenic mice. Oncogene 5, 535-542 (1990)

259. Liang T. J., A. E. Reid, R. Xavier, R. D. Cardiff, and T. C. Wang: Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors. J. Clin. Invest. 97, 2872-2877 (1996)

260. Kwan H., V. Pecenka, A. Tsukamoto, T. G. Parslow, R. Guzman, T. P. Lin, W. J. Muller, F. S. Lee, P. Leder, and H. E. Varmus: Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice. Mol Cell Biol 12, 147-154 (1992)

261. Muller W. J., F. S. Lee, C. Dickson, G. Peters, P. Pattengale, and P. Leder: The int-2 gene product acts as an epithelial growth factor in transgenic mice. EMBO J 9, 907-913 (1990)

262. Kitsberg D. I., and P. Leder: Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice. Oncogene 13, 2507-2515 (1996)

263. Krane I. M., and P. Leder: NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene 12, 1781-1788 (1996)

264. Takayama H., W. J. LaRochelle, R. Sharp, T. Otsuka, P. Kriebel, M. Anver, S. A. Aaronson, and G. Merlino: Proc. Natl. Acad. Sci. USA. 94, 701-706 (1997)

265. Bates P., R. Fisher, A. Ward, L. Richardson, D. J. Hill, and C. F. Graham: Mammary cancer in transgenic mice expressing insulin-like growth factor II. Br. J. Cancer 72, 1189-1193 (1995)

266. Pravtcheva D. D., and T. L. Wise: Metastasizing mammary carcinomas in H19 enhancers-Igf2 transgenic mice. J. Exp. Zool. 281, 43-57 (1998)

267. Coffey R. J. J., K. S. Meise, Y. Matsui, B. L. Hogan, P. J. Dempsey, and S. A. Halter: Acceleration of mammary neoplasia in transforming growth factor alpha transgenic mice by 7,12-dimethylbenzanthracene. Cancer Res. 54, 1678-1683 (1994)

268. Jhappan C., C. Stahle, R. N. Harkins, N. Fausto, G. H. Smith, and G. T. Merlino: TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 61, 1137-1146 (1990)

269. Matsui Y., S. A. Halter, J. T. Holt, B. L. Hogan, and R. J. Coffey: Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell 61, 1147-1155 (1990)

270. Sandgren E. P., N. C. Luetteke, R. D. Palmiter, R. L. Brinster, and D. C. Lee: Overexpression of TGF alpha in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61, 1121-1135 (1990)

271. Kordon E. C., R. A. McKnight, C. Jhappan, L. Hennighausen, G. Merlino, and G. H. Smith: Ectopic TGF beta 1 expression in the secretory mammary epithelium induces early senescence of the epithelial stem cell population. Dev. Biol. 168, 47-61 (1995)